WO1996031217A9 - Inhibiting retroviral replication - Google Patents
Inhibiting retroviral replicationInfo
- Publication number
- WO1996031217A9 WO1996031217A9 PCT/US1996/004084 US9604084W WO9631217A9 WO 1996031217 A9 WO1996031217 A9 WO 1996031217A9 US 9604084 W US9604084 W US 9604084W WO 9631217 A9 WO9631217 A9 WO 9631217A9
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- nitric oxide
- nitroso
- group
- animal
- retrovirus
- Prior art date
Links
- 230000002401 inhibitory effect Effects 0.000 title claims abstract description 39
- 230000001177 retroviral Effects 0.000 title claims abstract description 21
- MWUXSHHQAYIFBG-UHFFFAOYSA-N nitric oxide Chemical compound O=[N] MWUXSHHQAYIFBG-UHFFFAOYSA-N 0.000 claims abstract description 110
- 150000001875 compounds Chemical class 0.000 claims abstract description 76
- 241001430294 unidentified retrovirus Species 0.000 claims abstract description 37
- 239000000203 mixture Substances 0.000 claims abstract description 34
- 239000003443 antiviral agent Substances 0.000 claims abstract description 23
- 239000000236 nitric oxide synthase inhibitor Substances 0.000 claims abstract description 23
- 210000001519 tissues Anatomy 0.000 claims abstract description 22
- 208000005074 Retroviridae Infections Diseases 0.000 claims abstract description 18
- 239000002516 radical scavenger Substances 0.000 claims abstract description 10
- 239000003937 drug carrier Substances 0.000 claims abstract description 7
- 210000004027 cells Anatomy 0.000 claims description 81
- 241000282414 Homo sapiens Species 0.000 claims description 29
- 241000725303 Human immunodeficiency virus Species 0.000 claims description 26
- 125000000217 alkyl group Chemical group 0.000 claims description 21
- -1 hydroxy, carbamoyl Chemical group 0.000 claims description 20
- 229920001184 polypeptide Polymers 0.000 claims description 18
- 229910052739 hydrogen Inorganic materials 0.000 claims description 16
- 150000002431 hydrogen Chemical class 0.000 claims description 16
- 239000001257 hydrogen Substances 0.000 claims description 16
- 239000005541 ACE inhibitor Substances 0.000 claims description 10
- 239000000126 substance Substances 0.000 claims description 10
- MRAUNPAHJZDYCK-BYPYZUCNSA-N L-nitroarginine Chemical group OC(=O)[C@@H](N)CCCNC(=N)N[N+]([O-])=O MRAUNPAHJZDYCK-BYPYZUCNSA-N 0.000 claims description 9
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 9
- ICRHORQIUXBEPA-UHFFFAOYSA-N thionitrous acid Chemical compound SN=O ICRHORQIUXBEPA-UHFFFAOYSA-N 0.000 claims description 9
- 238000000338 in vitro Methods 0.000 claims description 7
- AHLPHDHHMVZTML-BYPYZUCNSA-N L-ornithine Chemical compound NCCC[C@H](N)C(O)=O AHLPHDHHMVZTML-BYPYZUCNSA-N 0.000 claims description 6
- 125000003545 alkoxy group Chemical group 0.000 claims description 6
- 125000003118 aryl group Chemical group 0.000 claims description 6
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims description 6
- 125000005843 halogen group Chemical group 0.000 claims description 6
- 125000004356 hydroxy functional group Chemical group O* 0.000 claims description 6
- 239000011780 sodium chloride Substances 0.000 claims description 6
- UAGYHIZGHDGMCY-FNCVBFRFSA-N (2R,3S,4R,5R)-2-(hydroxymethyl)-5-pyrimidin-1-ium-1-yloxolane-3,4-diol Chemical group O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1[N+]1=CC=CN=C1 UAGYHIZGHDGMCY-FNCVBFRFSA-N 0.000 claims description 5
- 239000011230 binding agent Substances 0.000 claims description 5
- 150000003839 salts Chemical class 0.000 claims description 5
- 208000000389 T-Cell Leukemia Diseases 0.000 claims description 4
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 4
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims description 4
- NTWVQPHTOUKMDI-YFKPBYRVSA-N (2S)-5-(diaminomethylideneamino)-2-(methylamino)pentanoic acid Chemical compound CN[C@H](C(O)=O)CCCN=C(N)N NTWVQPHTOUKMDI-YFKPBYRVSA-N 0.000 claims description 3
- AZGHTMLGGMHOBH-UHFFFAOYSA-N 1,2,2-trifluoropiperazine Chemical compound FN1CCNCC1(F)F AZGHTMLGGMHOBH-UHFFFAOYSA-N 0.000 claims description 3
- 229940023040 Acyclovir Drugs 0.000 claims description 3
- 102000014150 Interferons Human genes 0.000 claims description 3
- 108010050904 Interferons Proteins 0.000 claims description 3
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 claims description 3
- CXKWCBBOMKCUKX-UHFFFAOYSA-M Methylene blue Chemical compound [Cl-].C1=CC(N(C)C)=CC2=[S+]C3=CC(N(C)C)=CC=C3N=C21 CXKWCBBOMKCUKX-UHFFFAOYSA-M 0.000 claims description 3
- 229940042115 Methylene blue Drugs 0.000 claims description 3
- 229960003104 Ornithine Drugs 0.000 claims description 3
- 229960003962 Trifluridine Drugs 0.000 claims description 3
- VSQQQLOSPVPRAZ-RRKCRQDMSA-N Trifluridine Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(C(F)(F)F)=C1 VSQQQLOSPVPRAZ-RRKCRQDMSA-N 0.000 claims description 3
- 229960002555 Zidovudine Drugs 0.000 claims description 3
- HBOMLICNUCNMMY-XLPZGREQSA-N Zidovudine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](N=[N+]=[N-])C1 HBOMLICNUCNMMY-XLPZGREQSA-N 0.000 claims description 3
- 229960004150 aciclovir Drugs 0.000 claims description 3
- MKUXAQIIEYXACX-UHFFFAOYSA-N acyclovir Chemical compound N1C(N)=NC(=O)C2=C1N(COCCO)C=N2 MKUXAQIIEYXACX-UHFFFAOYSA-N 0.000 claims description 3
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims description 3
- 239000002738 chelating agent Substances 0.000 claims description 3
- WREGKURFCTUGRC-POYBYMJQSA-N ddC Chemical compound O=C1N=C(N)C=CN1[C@@H]1O[C@H](CO)CC1 WREGKURFCTUGRC-POYBYMJQSA-N 0.000 claims description 3
- BXZVVICBKDXVGW-NKWVEPMBSA-N ddIno Chemical compound O1[C@H](CO)CC[C@@H]1N1C(NC=NC2=O)=C2N=C1 BXZVVICBKDXVGW-NKWVEPMBSA-N 0.000 claims description 3
- 229960002656 didanosine Drugs 0.000 claims description 3
- QFXKXRXFBRLLPQ-UHFFFAOYSA-N diphenylene iodonium Chemical compound C1=CC=C2[I+]C3=CC=CC=C3C2=C1 QFXKXRXFBRLLPQ-UHFFFAOYSA-N 0.000 claims description 3
- 239000000138 intercalating agent Substances 0.000 claims description 3
- 229940079322 interferon Drugs 0.000 claims description 3
- MGFYSGNNHQQTJW-UHFFFAOYSA-N iodonium Chemical class [IH2+] MGFYSGNNHQQTJW-UHFFFAOYSA-N 0.000 claims description 3
- 229960000485 methotrexate Drugs 0.000 claims description 3
- 229960000907 methylthioninium chloride Drugs 0.000 claims description 3
- 229910052757 nitrogen Inorganic materials 0.000 claims description 3
- XKLJHFLUAHKGGU-UHFFFAOYSA-N nitrous amide Chemical class ON=N XKLJHFLUAHKGGU-UHFFFAOYSA-N 0.000 claims description 3
- 150000003834 purine nucleoside derivatives Chemical class 0.000 claims description 3
- NINIDFKCEFEMDL-UHFFFAOYSA-N sulfur Chemical group [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 claims description 3
- 229910052717 sulfur Chemical group 0.000 claims description 3
- 239000011593 sulfur Chemical group 0.000 claims description 3
- 229960000523 zalcitabine Drugs 0.000 claims description 3
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 claims description 2
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 claims description 2
- 125000000094 2-phenylethyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])([H])* 0.000 claims description 2
- 150000004006 C-nitroso compounds Chemical class 0.000 claims description 2
- ZSRSLWKGWFFVCM-WDSKDSINSA-N Cys-Pro Chemical compound SC[C@H](N)C(=O)N1CCC[C@H]1C(O)=O ZSRSLWKGWFFVCM-WDSKDSINSA-N 0.000 claims description 2
- 125000005118 N-alkylcarbamoyl group Chemical group 0.000 claims description 2
- 108091005615 S-nitrosylated proteins Proteins 0.000 claims description 2
- 125000003282 alkyl amino group Chemical group 0.000 claims description 2
- 125000004644 alkyl sulfinyl group Chemical group 0.000 claims description 2
- 125000002178 anthracenyl group Chemical group C1(=CC=CC2=CC3=CC=CC=C3C=C12)* 0.000 claims description 2
- 125000005110 aryl thio group Chemical group 0.000 claims description 2
- 125000004063 butyryl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 claims description 2
- 125000001589 carboacyl group Chemical group 0.000 claims description 2
- 125000005518 carboxamido group Chemical group 0.000 claims description 2
- 125000004093 cyano group Chemical group *C#N 0.000 claims description 2
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 2
- 125000004663 dialkyl amino group Chemical group 0.000 claims description 2
- AZLYZRGJCVQKKK-UHFFFAOYSA-N dioxohydrazine Chemical class O=NN=O AZLYZRGJCVQKKK-UHFFFAOYSA-N 0.000 claims description 2
- 125000001153 fluoro group Chemical group F* 0.000 claims description 2
- 229910052736 halogen Inorganic materials 0.000 claims description 2
- 150000002367 halogens Chemical group 0.000 claims description 2
- 150000002500 ions Chemical class 0.000 claims description 2
- 125000001624 naphthyl group Chemical group 0.000 claims description 2
- 150000002823 nitrates Chemical class 0.000 claims description 2
- 229910052760 oxygen Inorganic materials 0.000 claims description 2
- MYMOFIZGZYHOMD-UHFFFAOYSA-N oxygen Chemical group O=O MYMOFIZGZYHOMD-UHFFFAOYSA-N 0.000 claims description 2
- 239000001301 oxygen Substances 0.000 claims description 2
- 125000000951 phenoxy group Chemical group [H]C1=C([H])C([H])=C(O*)C([H])=C1[H] 0.000 claims description 2
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 2
- 125000000565 sulfonamide group Chemical group 0.000 claims description 2
- MRWXACSTFXYYMV-FDDDBJFASA-N NEBULARINE Chemical group O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C2=NC=NC=C2N=C1 MRWXACSTFXYYMV-FDDDBJFASA-N 0.000 claims 2
- OWEDDXNGGLTCTB-GKAPJAKFSA-N (2S)-1-[5-(diaminomethylideneamino)-2-(nitrososulfanylmethyl)pentanoyl]pyrrolidine-2-carboxylic acid Chemical compound NC(=N)NCCCC(CSN=O)C(=O)N1CCC[C@H]1C(O)=O OWEDDXNGGLTCTB-GKAPJAKFSA-N 0.000 claims 1
- 125000006701 (C1-C7) alkyl group Chemical group 0.000 claims 1
- 229960002591 Hydroxyproline Drugs 0.000 claims 1
- 229960002429 Proline Drugs 0.000 claims 1
- 125000005466 alkylenyl group Chemical group 0.000 claims 1
- 125000003884 phenylalkyl group Chemical group 0.000 claims 1
- 206010038997 Retroviral infection Diseases 0.000 abstract description 2
- ZIIQCSMRQKCOCT-YFKPBYRVSA-N S-Nitroso-N-acetylpenicillamine Chemical compound CC(=O)N[C@@H](C(O)=O)C(C)(C)SN=O ZIIQCSMRQKCOCT-YFKPBYRVSA-N 0.000 description 25
- 235000001014 amino acid Nutrition 0.000 description 20
- MNNBCKASUFBXCO-YFKPBYRVSA-N N-acetyl-D-penicillamine Chemical compound CC(=O)N[C@@H](C(O)=O)C(C)(C)S MNNBCKASUFBXCO-YFKPBYRVSA-N 0.000 description 19
- 230000000694 effects Effects 0.000 description 19
- 102100001172 TPPP Human genes 0.000 description 18
- 150000001413 amino acids Chemical class 0.000 description 18
- 150000002430 hydrocarbons Chemical class 0.000 description 16
- 239000004215 Carbon black (E152) Substances 0.000 description 15
- QTJKCQPXTOYYHJ-BYPYZUCNSA-N (2R)-2-acetamido-3-nitrososulfanylpropanoic acid Chemical compound CC(=O)N[C@H](C(O)=O)CSN=O QTJKCQPXTOYYHJ-BYPYZUCNSA-N 0.000 description 14
- 210000003819 Peripheral blood mononuclear cell Anatomy 0.000 description 14
- 241000713772 Human immunodeficiency virus 1 Species 0.000 description 13
- 201000009910 diseases by infectious agent Diseases 0.000 description 13
- 229960004308 ACETYLCYSTEINE Drugs 0.000 description 11
- PWKSKIMOESPYIA-BYPYZUCNSA-N L-N-acetyl-Cysteine Chemical compound CC(=O)N[C@@H](CS)C(O)=O PWKSKIMOESPYIA-BYPYZUCNSA-N 0.000 description 11
- 102100002496 NOS2 Human genes 0.000 description 11
- 239000000427 antigen Substances 0.000 description 11
- 102000038129 antigens Human genes 0.000 description 11
- 108091007172 antigens Proteins 0.000 description 11
- 235000018102 proteins Nutrition 0.000 description 11
- 102000004169 proteins and genes Human genes 0.000 description 11
- 108090000623 proteins and genes Proteins 0.000 description 11
- 101700049309 NOS2 Proteins 0.000 description 10
- 230000035755 proliferation Effects 0.000 description 10
- 230000000699 topical Effects 0.000 description 10
- 241000700605 Viruses Species 0.000 description 9
- ZOOGRGPOEVQQDX-UUOKFMHZSA-N Cyclic guanosine monophosphate Chemical compound C([C@H]1O2)OP(O)(=O)O[C@H]1[C@@H](O)[C@@H]2N1C(N=C(NC2=O)N)=C2N=C1 ZOOGRGPOEVQQDX-UUOKFMHZSA-N 0.000 description 7
- 102000008299 Nitric Oxide Synthase Human genes 0.000 description 7
- 108010021487 Nitric Oxide Synthase Proteins 0.000 description 7
- 229920000272 Oligonucleotide Polymers 0.000 description 7
- 241000700159 Rattus Species 0.000 description 7
- URRBLVUOXIGNQR-HXUWFJFHSA-N [(1R)-1-phenylethyl] N-(2-aminoethyl)-N-[(3-methoxy-4-phenylmethoxyphenyl)methyl]carbamate Chemical compound C1([C@@H](C)OC(=O)N(CCN)CC=2C=C(C(=CC=2)OCC=2C=CC=CC=2)OC)=CC=CC=C1 URRBLVUOXIGNQR-HXUWFJFHSA-N 0.000 description 7
- 150000001338 aliphatic hydrocarbons Chemical class 0.000 description 7
- 150000004945 aromatic hydrocarbons Chemical class 0.000 description 7
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 7
- 150000002391 heterocyclic compounds Chemical class 0.000 description 7
- 239000002773 nucleotide Substances 0.000 description 7
- 125000003729 nucleotide group Chemical group 0.000 description 7
- 229920001308 poly(aminoacid) Polymers 0.000 description 7
- 125000001424 substituent group Chemical group 0.000 description 7
- 235000000346 sugar Nutrition 0.000 description 7
- 150000008163 sugars Chemical class 0.000 description 7
- QLPXHECKUSZTMH-VKHMYHEASA-N (2S)-2-amino-3-methyl-3-nitrososulfanylbutanoic acid Chemical compound O=NSC(C)(C)[C@@H](N)C(O)=O QLPXHECKUSZTMH-VKHMYHEASA-N 0.000 description 6
- 102000001554 Hemoglobins Human genes 0.000 description 6
- 108010054147 Hemoglobins Proteins 0.000 description 6
- 201000010099 disease Diseases 0.000 description 6
- 238000002474 experimental method Methods 0.000 description 6
- 238000002965 ELISA Methods 0.000 description 5
- 229920000903 Polyhydroxyalkanoate Polymers 0.000 description 5
- 230000015572 biosynthetic process Effects 0.000 description 5
- 239000003795 chemical substances by application Substances 0.000 description 5
- 238000001990 intravenous administration Methods 0.000 description 5
- 229910052751 metal Inorganic materials 0.000 description 5
- 239000002184 metal Substances 0.000 description 5
- 239000002840 nitric oxide donor Substances 0.000 description 5
- 238000003786 synthesis reaction Methods 0.000 description 5
- 230000002194 synthesizing Effects 0.000 description 5
- 230000001225 therapeutic Effects 0.000 description 5
- 150000003573 thiols Chemical class 0.000 description 5
- 108010002350 Interleukin-2 Proteins 0.000 description 4
- ODKSFYDXXFIFQN-BYPYZUCNSA-N L-arginine Chemical compound OC(=O)[C@@H](N)CCCN=C(N)N ODKSFYDXXFIFQN-BYPYZUCNSA-N 0.000 description 4
- VVNCNSJFMMFHPL-VKHMYHEASA-N Penicillamine Chemical compound CC(C)(S)[C@@H](N)C(O)=O VVNCNSJFMMFHPL-VKHMYHEASA-N 0.000 description 4
- 241000713311 Simian immunodeficiency virus Species 0.000 description 4
- 230000000840 anti-viral Effects 0.000 description 4
- 231100000673 dose–response relationship Toxicity 0.000 description 4
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 4
- 238000004519 manufacturing process Methods 0.000 description 4
- 239000002609 media Substances 0.000 description 4
- 229960001639 penicillamine Drugs 0.000 description 4
- 239000000725 suspension Substances 0.000 description 4
- 229920000160 (ribonucleotides)n+m Polymers 0.000 description 3
- YUFCOOWNNHGGOD-UMMCILCDSA-N 8-Bromoguanosine 3',5'-cyclic monophosphate Chemical compound C([C@H]1O2)OP(O)(=O)O[C@H]1[C@@H](O)[C@@H]2N1C(N=C(NC2=O)N)=C2N=C1Br YUFCOOWNNHGGOD-UMMCILCDSA-N 0.000 description 3
- 229920002676 Complementary DNA Polymers 0.000 description 3
- IQFYYKKMVGJFEH-XLPZGREQSA-N DEOXYTHYMIDINE Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 IQFYYKKMVGJFEH-XLPZGREQSA-N 0.000 description 3
- 239000007759 RPMI Media 1640 Substances 0.000 description 3
- 230000037396 body weight Effects 0.000 description 3
- 239000000969 carrier Substances 0.000 description 3
- 239000002299 complementary DNA Substances 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 239000012091 fetal bovine serum Substances 0.000 description 3
- 238000001802 infusion Methods 0.000 description 3
- 239000004615 ingredient Substances 0.000 description 3
- 239000003112 inhibitor Substances 0.000 description 3
- 238000002347 injection Methods 0.000 description 3
- 239000007924 injection Substances 0.000 description 3
- 238000000034 method Methods 0.000 description 3
- OZAIFHULBGXAKX-UHFFFAOYSA-N precursor Substances N#CC(C)(C)N=NC(C)(C)C#N OZAIFHULBGXAKX-UHFFFAOYSA-N 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 238000002560 therapeutic procedure Methods 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- 102100001249 ALB Human genes 0.000 description 2
- 239000004475 Arginine Substances 0.000 description 2
- 102000014469 EC 4.6.1.2 Human genes 0.000 description 2
- 108010078321 EC 4.6.1.2 Proteins 0.000 description 2
- 235000014852 L-arginine Nutrition 0.000 description 2
- GUBGYTABKSRVRQ-UUNJERMWSA-N Lactose Natural products O([C@@H]1[C@H](O)[C@H](O)[C@H](O)O[C@@H]1CO)[C@H]1[C@@H](O)[C@@H](O)[C@H](O)[C@H](CO)O1 GUBGYTABKSRVRQ-UUNJERMWSA-N 0.000 description 2
- 210000002540 Macrophages Anatomy 0.000 description 2
- 230000004913 activation Effects 0.000 description 2
- 239000003708 ampul Substances 0.000 description 2
- 230000001028 anti-proliferant Effects 0.000 description 2
- 235000009697 arginine Nutrition 0.000 description 2
- 238000004166 bioassay Methods 0.000 description 2
- 150000001768 cations Chemical class 0.000 description 2
- 230000001413 cellular Effects 0.000 description 2
- 239000011248 coating agent Substances 0.000 description 2
- 238000000576 coating method Methods 0.000 description 2
- 239000006071 cream Substances 0.000 description 2
- 235000014113 dietary fatty acids Nutrition 0.000 description 2
- 150000002019 disulfides Chemical class 0.000 description 2
- 239000003995 emulsifying agent Substances 0.000 description 2
- 239000000839 emulsion Substances 0.000 description 2
- 239000000194 fatty acid Substances 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- XEEYBQQBJWHFJM-UHFFFAOYSA-N iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 2
- 239000008101 lactose Substances 0.000 description 2
- GUBGYTABKSRVRQ-XLOQQCSPSA-N lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 2
- 230000002101 lytic Effects 0.000 description 2
- 235000019359 magnesium stearate Nutrition 0.000 description 2
- KEJOCWOXCDWNID-UHFFFAOYSA-N nitrosonium Chemical compound [O+]#N KEJOCWOXCDWNID-UHFFFAOYSA-N 0.000 description 2
- 230000000269 nucleophilic Effects 0.000 description 2
- 239000008194 pharmaceutical composition Substances 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 238000003757 reverse transcription PCR Methods 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 241000894007 species Species 0.000 description 2
- 239000003381 stabilizer Substances 0.000 description 2
- 125000004354 sulfur functional group Chemical group 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 125000003396 thiol group Chemical group [H]S* 0.000 description 2
- ZMANZCXQSJIPKH-UHFFFAOYSA-N triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 2
- 238000001262 western blot Methods 0.000 description 2
- 239000000080 wetting agent Substances 0.000 description 2
- 239000012130 whole-cell lysate Substances 0.000 description 2
- HNIULCDUASSKOM-RQJHMYQMSA-N (2S)-1-[(2S)-2-methyl-3-nitrososulfanylpropanoyl]pyrrolidine-2-carboxylic acid Chemical compound O=NSC[C@@H](C)C(=O)N1CCC[C@H]1C(O)=O HNIULCDUASSKOM-RQJHMYQMSA-N 0.000 description 1
- QWPCKAAAWDCDCW-VKHMYHEASA-N (2S)-2-amino-4-nitrososulfanylbutanoic acid Chemical compound OC(=O)[C@@H](N)CCSN=O QWPCKAAAWDCDCW-VKHMYHEASA-N 0.000 description 1
- SNIOPGDIGTZGOP-UHFFFAOYSA-N 1,2,3-propanetrioltrinitrate Chemical group [O-][N+](=O)OCC(O[N+]([O-])=O)CO[N+]([O-])=O SNIOPGDIGTZGOP-UHFFFAOYSA-N 0.000 description 1
- MIJDSYMOBYNHOT-UHFFFAOYSA-N 2-(ethylamino)ethanol Chemical compound CCNCCO MIJDSYMOBYNHOT-UHFFFAOYSA-N 0.000 description 1
- XOWVFANEOZMPKG-UHFFFAOYSA-N 2-amino-3-nitrososulfanylpropanoic acid Chemical compound OC(=O)C(N)CSN=O XOWVFANEOZMPKG-UHFFFAOYSA-N 0.000 description 1
- NTPCHAXHWPDMEI-UHFFFAOYSA-N 5-amino-2,4-dimethylbenzenesulfonic acid Chemical compound CC1=CC(C)=C(S(O)(=O)=O)C=C1N NTPCHAXHWPDMEI-UHFFFAOYSA-N 0.000 description 1
- 101710027066 ALB Proteins 0.000 description 1
- 229920000856 Amylose Polymers 0.000 description 1
- 210000001772 Blood Platelets Anatomy 0.000 description 1
- 102000000584 Calmodulin Human genes 0.000 description 1
- 108010041952 Calmodulin Proteins 0.000 description 1
- 102000014914 Carrier Proteins Human genes 0.000 description 1
- 108010078791 Carrier Proteins Proteins 0.000 description 1
- 102000004225 Cathepsin B Human genes 0.000 description 1
- 108090000712 Cathepsin B Proteins 0.000 description 1
- 210000000170 Cell Membrane Anatomy 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-KAZBKCHUSA-N D-Mannitol Natural products OC[C@@H](O)[C@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KAZBKCHUSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- 206010011878 Deafness Diseases 0.000 description 1
- 229920002307 Dextran Polymers 0.000 description 1
- 108010092799 EC 2.7.7.49 Proteins 0.000 description 1
- 102000033147 ERVK-25 Human genes 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 208000001860 Eye Infections Diseases 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 206010061978 Genital lesion Diseases 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-N HCl Chemical class Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 1
- 208000005721 HIV Infections Diseases 0.000 description 1
- 229940031574 HYDROXYMETHYL CELLULOSE Drugs 0.000 description 1
- 102000008015 Hemeproteins Human genes 0.000 description 1
- 108010089792 Hemeproteins Proteins 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 229940072221 IMMUNOGLOBULINS Drugs 0.000 description 1
- 102100016057 ISYNA1 Human genes 0.000 description 1
- 101710004164 ISYNA1 Proteins 0.000 description 1
- 206010061598 Immunodeficiency Diseases 0.000 description 1
- 102000018358 Immunoglobulins Human genes 0.000 description 1
- 108060003951 Immunoglobulins Proteins 0.000 description 1
- 108090000467 Interferon beta Proteins 0.000 description 1
- 102000003996 Interferon beta Human genes 0.000 description 1
- 102000008070 Interferon-gamma Human genes 0.000 description 1
- 108010074328 Interferon-gamma Proteins 0.000 description 1
- 210000004347 Intestinal Mucosa Anatomy 0.000 description 1
- JJWLVOIRVHMVIS-UHFFFAOYSA-N Isopropylamine Chemical compound CC(C)N JJWLVOIRVHMVIS-UHFFFAOYSA-N 0.000 description 1
- KLDXJTOLSGUMSJ-JGWLITMVSA-N Isosorbide Chemical compound O[C@@H]1CO[C@@H]2[C@@H](O)CO[C@@H]21 KLDXJTOLSGUMSJ-JGWLITMVSA-N 0.000 description 1
- 229960002479 Isosorbide Drugs 0.000 description 1
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 description 1
- 102000004895 Lipoproteins Human genes 0.000 description 1
- 108090001030 Lipoproteins Proteins 0.000 description 1
- 206010024774 Localised infection Diseases 0.000 description 1
- 206010061229 Lung infection Diseases 0.000 description 1
- 210000004698 Lymphocytes Anatomy 0.000 description 1
- ZLNQQNXFFQJAID-UHFFFAOYSA-L Magnesium carbonate Chemical compound [Mg+2].[O-]C([O-])=O ZLNQQNXFFQJAID-UHFFFAOYSA-L 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- 210000004379 Membranes Anatomy 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 210000002200 Mouth Mucosa Anatomy 0.000 description 1
- 210000002464 Muscle, Smooth, Vascular Anatomy 0.000 description 1
- 125000003047 N-acetyl group Chemical group 0.000 description 1
- 108010076864 Nitric Oxide Synthase Type II Proteins 0.000 description 1
- 229940014995 Nitroglycerin Drugs 0.000 description 1
- 239000000006 Nitroglycerin Substances 0.000 description 1
- 229960002460 Nitroprusside Drugs 0.000 description 1
- ODKSFYDXXFIFQN-SCSAIBSYSA-N OC(=O)[C@H](N)CCCNC(N)=N Chemical compound OC(=O)[C@H](N)CCCNC(N)=N ODKSFYDXXFIFQN-SCSAIBSYSA-N 0.000 description 1
- 206010067621 Oral disease Diseases 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 229940023488 Pill Drugs 0.000 description 1
- MFDFERRIHVXMIY-UHFFFAOYSA-N Procaine Chemical compound CCN(CC)CCOC(=O)C1=CC=C(N)C=C1 MFDFERRIHVXMIY-UHFFFAOYSA-N 0.000 description 1
- 102000014961 Protein Precursors Human genes 0.000 description 1
- 108010078762 Protein Precursors Proteins 0.000 description 1
- 206010057190 Respiratory tract infection Diseases 0.000 description 1
- 108010001742 S-Nitrosoglutathione Proteins 0.000 description 1
- HYHSBSXUHZOYLX-WDSKDSINSA-N S-nitrosoglutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CSN=O)C(=O)NCC(O)=O HYHSBSXUHZOYLX-WDSKDSINSA-N 0.000 description 1
- CVHZOJJKTDOEJC-UHFFFAOYSA-N Saccharin Chemical compound C1=CC=C2C(=O)NS(=O)(=O)C2=C1 CVHZOJJKTDOEJC-UHFFFAOYSA-N 0.000 description 1
- 108010071390 Serum Albumin Proteins 0.000 description 1
- RMAQACBXLXPBSY-UHFFFAOYSA-N Silicic acid Chemical compound O[Si](O)(O)O RMAQACBXLXPBSY-UHFFFAOYSA-N 0.000 description 1
- 206010040872 Skin infection Diseases 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 101710040537 TNF Proteins 0.000 description 1
- 241000906446 Theraps Species 0.000 description 1
- 229940104230 Thymidine Drugs 0.000 description 1
- 102000003978 Tissue plasminogen activator Human genes 0.000 description 1
- 108090000373 Tissue plasminogen activator Proteins 0.000 description 1
- GLNADSQYFUSGOU-GPTZEZBUSA-J Trypan blue Chemical compound [Na+].[Na+].[Na+].[Na+].C1=C(S([O-])(=O)=O)C=C2C=C(S([O-])(=O)=O)C(/N=N/C3=CC=C(C=C3C)C=3C=C(C(=CC=3)\N=N\C=3C(=CC4=CC(=CC(N)=C4C=3O)S([O-])(=O)=O)S([O-])(=O)=O)C)=C(O)C2=C1N GLNADSQYFUSGOU-GPTZEZBUSA-J 0.000 description 1
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 1
- 108010001801 Tumor Necrosis Factor-alpha Proteins 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O Chemical class [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 235000011054 acetic acid Nutrition 0.000 description 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000002378 acidificating Effects 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 230000001058 adult Effects 0.000 description 1
- 229940050528 albumin Drugs 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- 150000003862 amino acid derivatives Chemical class 0.000 description 1
- 125000003277 amino group Chemical group 0.000 description 1
- QGZKDVFQNNGYKY-UHFFFAOYSA-O ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 239000012062 aqueous buffer Substances 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 239000007900 aqueous suspension Substances 0.000 description 1
- 150000001483 arginine derivatives Chemical class 0.000 description 1
- 238000003287 bathing Methods 0.000 description 1
- UIIMBOGNXHQVGW-UHFFFAOYSA-M buffer Substances [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- GUTLYIVDDKVIGB-UHFFFAOYSA-N cobalt Chemical compound [Co] GUTLYIVDDKVIGB-UHFFFAOYSA-N 0.000 description 1
- 229910052803 cobalt Inorganic materials 0.000 description 1
- 239000010941 cobalt Substances 0.000 description 1
- 230000002860 competitive Effects 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 229910052802 copper Inorganic materials 0.000 description 1
- RYGMFSIKBFXOCR-UHFFFAOYSA-N copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 1
- 239000010949 copper Substances 0.000 description 1
- 229920003013 deoxyribonucleic acid Polymers 0.000 description 1
- 230000001419 dependent Effects 0.000 description 1
- 150000004662 dithiols Chemical class 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 229940079593 drugs Drugs 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 238000005538 encapsulation Methods 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 229960000848 foscarnet sodium Drugs 0.000 description 1
- 229940044627 gamma-interferon Drugs 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 229960003711 glyceryl trinitrate Drugs 0.000 description 1
- 150000003278 haem Chemical class 0.000 description 1
- 230000002440 hepatic Effects 0.000 description 1
- 125000000623 heterocyclic group Chemical group 0.000 description 1
- 201000001820 human immunodeficiency virus infectious disease Diseases 0.000 description 1
- 235000011167 hydrochloric acid Nutrition 0.000 description 1
- 150000004679 hydroxides Chemical class 0.000 description 1
- 229920003063 hydroxymethyl cellulose Polymers 0.000 description 1
- 239000007943 implant Substances 0.000 description 1
- 238000010874 in vitro model Methods 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 239000000543 intermediate Substances 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 229910052742 iron Inorganic materials 0.000 description 1
- 239000006193 liquid solution Substances 0.000 description 1
- 239000003589 local anesthetic agent Substances 0.000 description 1
- 239000006210 lotion Substances 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 239000001095 magnesium carbonate Substances 0.000 description 1
- 239000011776 magnesium carbonate Substances 0.000 description 1
- 229910000021 magnesium carbonate Inorganic materials 0.000 description 1
- PWHULOQIROXLJO-UHFFFAOYSA-N manganese Chemical compound [Mn] PWHULOQIROXLJO-UHFFFAOYSA-N 0.000 description 1
- 229910052748 manganese Inorganic materials 0.000 description 1
- 239000011572 manganese Substances 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000001404 mediated Effects 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 150000002739 metals Chemical class 0.000 description 1
- 239000003094 microcapsule Substances 0.000 description 1
- 239000011859 microparticle Substances 0.000 description 1
- 230000000116 mitigating Effects 0.000 description 1
- 230000001264 neutralization Effects 0.000 description 1
- 150000002826 nitrites Chemical class 0.000 description 1
- ASPOIVQEUUCDQT-UHFFFAOYSA-N nitroprusside Chemical compound O=N[Fe-2](C#N)(C#N)(C#N)(C#N)C#N ASPOIVQEUUCDQT-UHFFFAOYSA-N 0.000 description 1
- 238000007034 nitrosation reaction Methods 0.000 description 1
- 125000000018 nitroso group Chemical group N(=O)* 0.000 description 1
- 108091005614 nitrosylated proteins Proteins 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 235000019198 oils Nutrition 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 230000003204 osmotic Effects 0.000 description 1
- 239000006179 pH buffering agent Substances 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 239000002304 perfume Substances 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 229920000406 phosphotungstic acid polymer Polymers 0.000 description 1
- 238000006303 photolysis reaction Methods 0.000 description 1
- 230000015843 photosynthesis, light reaction Effects 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 229920002401 polyacrylamide Polymers 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 230000002335 preservative Effects 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 229960004919 procaine Drugs 0.000 description 1
- 230000001737 promoting Effects 0.000 description 1
- 230000001681 protective Effects 0.000 description 1
- 230000002829 reduced Effects 0.000 description 1
- 230000001105 regulatory Effects 0.000 description 1
- 230000003362 replicative Effects 0.000 description 1
- 239000012266 salt solution Substances 0.000 description 1
- BUGBHKTXTAQXES-UHFFFAOYSA-N selenium Chemical compound [Se] BUGBHKTXTAQXES-UHFFFAOYSA-N 0.000 description 1
- 229910052711 selenium Inorganic materials 0.000 description 1
- 239000011669 selenium Substances 0.000 description 1
- 235000012239 silicon dioxide Nutrition 0.000 description 1
- KEAYESYHFKHZAL-UHFFFAOYSA-N sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000008227 sterile water for injection Substances 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 230000002459 sustained Effects 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 235000012222 talc Nutrition 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- 229910052723 transition metal Inorganic materials 0.000 description 1
- 150000003624 transition metals Chemical class 0.000 description 1
- 150000003626 triacylglycerols Chemical class 0.000 description 1
- DFHAXXVZCFXGOQ-UHFFFAOYSA-K trisodium phosphonoformate Chemical compound [Na+].[Na+].[Na+].[O-]C(=O)P([O-])([O-])=O DFHAXXVZCFXGOQ-UHFFFAOYSA-K 0.000 description 1
- 125000004417 unsaturated alkyl group Chemical group 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 239000003981 vehicle Substances 0.000 description 1
Definitions
- This invention relates to the field of inhibiting retroviral replication in vitro and in vivo and to the treatment in humans and other animals of active and latent retroviral infections.
- the invention is based on the discovery by the inventors that nitric oxide and adducts thereof which are nitric oxide donors inhibit retroviral replication and provides a method for inhibiting the replication of a retrovirus by exposing the retrovirus to nitric oxide or a nitric oxide-releasing, donating or transferring substance.
- the present invention provides a method for inhibiting retroviral replication in a retrovirally infected cell or tissue culture in vitro which comprises contacting said retrovirally infected cell or tissue culture with an amount of nitric oxide or a nitric oxide-delivering, releasing or transferring compound sufficient to inhibit retroviral replication in said retrovirally infected cell or tissue culture.
- Another aspect of the invention provides a method for inhibiting retroviral replication in a retrovirally
- Another aspect of the invention provides a method for inhibiting retroviral replication in a retrovirally infected individual which comprises administering to said retrovirally infected individual an amount of nitric oxide or a nitric oxide-delivering, releasing or transferring compound sufficient to inhibit retroviral replication in said retrovirally infected individual.
- Another aspect of the invention provides a method for inhibiting the reactivation of latent retrovirus in a retrovirally infected cell or tissue culture which comprises contacting said retrovirally infected cell or tissue culture with a retrovirus reactivation inhibiting amount of nitric oxide, or a nitric oxide releasing, donating, or transferring substance which may be used prophylactically to prevent reactivation of latent retrovirus. This is very useful in mitigating the dangers of sample handling for research, laboratory and hospital personnel.
- Another aspect of the invention provides a method for inhibiting the reactivation of a latent retrovirus infection in an animal in need thereof which comprises administering to said animal in need thereof an amount of nitric oxide, or a nitric oxide releasing, donating, or transferring substance sufficient to inhibit reactivation of latent retrovirus in said animal.
- Another aspect of the invention provides a method for inhibiting the reactivation of a latent retrovirus infection in an individual in need thereof which comprises administering to an individual in need thereof an amount of nitric oxide, or a nitric oxide releasing, donating, or transferring substance sufficient to inhibit reactivation of latent retrovirus in said individual.
- This is very useful, for example, in an immunocompromised host in which reactivation at an inopportune time (e.g. when defenses are low due to chemotherapy) would cause significant morbidity.
- the invention is further based on the discovery by the inventors that nitric oxide synthase inhibitors and nitric oxide scavengers activate latent retrovirus. This is the first demonstration of a mechanism for eradicating the latent state, i.e., once activated, the retrovirus can then be eliminated with antiviral therapy. Thus, this aspect of the present invention is directed to the use of nitric oxide synthase inhibitors as a means to eradicate latent virus.
- another aspect of the invention provides a method for preventing or reversing retroviral latency in a retrovirally infected cell or tissue culture in vitro which comprises contacting a retrovirally infected cell or tissue culture in vitro with a nitric oxide synthase inhibitor or nitric oxide scavenger, such as hemoglobin, in an amount sufficient to render the latent retrovirus in the retrovirally infected cell or tissue culture replication-competent.
- a nitric oxide synthase inhibitor or nitric oxide scavenger such as hemoglobin
- compositions for the treatment of a latent retrovirus infection in an animal infected with a latent retrovirus infection which comprises (i) a nitric oxide synthase inhibitor or nitric oxide scavenger, such as hemoglobin, in an amount sufficient to render the retrovirus infecting said animal replication-competent and (ii) a retrovirus replication inhibitory amount of an antiviral agent in a pharmaceutically acceptable carrier.
- Another aspect of the invention provides a method for the treatment of a latent retrovirus infection in an animal infected with a latent retrovirus infection which comprises administering thereto (i) a nitric oxide synthase inhibitor or nitric oxide scavenger, such as hemoglobin, in an amount sufficient to render the retrovirus infecting said animal replication-competent and (ii) a retroviral replication inhibitory amount of an antiviral agent.
- a nitric oxide synthase inhibitor or nitric oxide scavenger such as hemoglobin
- compositions for the treatment of a latent retrovirus infection in an individual infected with a latent retrovirus infection which comprises (i) a nitric oxide synthase inhibitor or nitric oxide scavenger, such as hemoglobin, in an amount sufficient to render the retrovirus infecting said individual replication- competent and (ii) a retrovirus replication inhibitory amount of an antiviral agent in a pharmaceutically acceptable carrier.
- Another aspect of the invention provides a method for the treatment of a latent retrovirus infection in an individual infected with a latent retrovirus infection which comprises administering thereto (i) a nitric oxide synthase inhibitor or nitric oxide scavenger, such as hemoglobin, in an amount sufficient to render the retrovirus infecting said individual replication- competent and (ii) a retroviral replication inhibitory amount of an antiviral agent.
- a nitric oxide synthase inhibitor or nitric oxide scavenger such as hemoglobin
- Retroviruses whose growth may be inhibited in accordance with the method of the present invention include, but are not limited to, human immunodeficiency virus (HIV) , human T-cell leukemia virus-1 (HTLV-1) and simian immunodeficiency virus (SIV) .
- the administration can be topical, by inhalation, oral, or parenteral.
- the treated infection can be localized or systemic.
- Figures 1A-1D show that NO generating compounds inhibit HIV-1 replication in human peripheral blood mononuclear cells and in the chronically infected human T cell line H9:
- Figure 1A shows results when human peripheral blood mononuclear cells (PBMC ⁇ ) stimulated with PHA and IL-2 were infected with HIV-1, and then grown in the presence or absence of the NO generating compound S- nitroso-N-acetyl-penicillamine (SNAP) , or the parent compound N-acetyl-penicillamine (NAP) ;
- PBMC ⁇ peripheral blood mononuclear cells
- SNAP S- nitroso-N-acetyl-penicillamine
- NAP N-acetyl-penicillamine
- IB shows the results when the same experiment as shown in Figure 1A was performed using the NO-generating compound S-nitroso-N-acetyl-cysteine (SNAC) or the parent compound N-acetyl cysteine (NAC) ;
- Figure 1C shows the results when H9 cells were grown in the presence or absence of the NO generating compound SNAP.
- Figure ID shows the results when the same experiment as shown in Figure 1C was performed using the NO generating compound S-nitroso-penicillamine (SNP) or the control compound penicillamine (P) .
- Figures 2A-2B show the effect of NO on PBMC proliferation:
- Figure 2A shows the results when human peripheral blood mononuclear cells are stimulated with PHA and IL-2 were grown in the presence or absence of the NO-generating compound SNAP or the parent compound NAP;
- Figure 2B shows the results when the same experiment as shown in Figure 2A was performed using the NO-generating compound S-nitroso-N-acetyl cysteine (SNAC) or the control compound N-acetyl cysteine (NAC) .
- SNAC NO-generating compound S-nitroso-N-acetyl cysteine
- NAC control compound N-acetyl cysteine
- Figures 3A-3B show that iNOS is expressed constitutively in U-937 cells;
- Figure 3A shows cDNA that was made from whole cell RNA from U-937 or from the control B cell line B-958 which is known to express iNOS; and
- Figure 3B shows a western blot that was performed on whole cell lysates made from 0.5xl0 6 U-937 cells (U-937), the human B cell line BL-30, and rat macrophages stimulated with LPS (Rat) .
- Figures 4A-4B show that endogenously produced NO inhibits HIV replication and HIV reactivation:
- Figure 4A shows the results when U-937 cells were infected with HIV-1 and then grown in the presence or absence of the NOS inhibitor L-NMA; and Figure 4B shows the results when the latently infected Ul cell line was grown in the presence or absence of L-NMA and TNFCU.
- Figure 5 shows the effect of cGMP on HIV replication.
- Peripheral blood mononuclear cells were infected with HIV-1 and then grown in the presence or absence of SNAP, NAP or the cGMP analog 8-bromo-cGMP.
- nitric oxide and compounds that release nitric oxide or otherwise directly or indirectly deliver or transfer nitric oxide to a site of its activity, such as on a cell membrane, in vivo.
- nitric oxide encompasses uncharged nitric oxide(N0«) and charged nitric oxide species, particularly including nitrosonium ion(NO + ) and nitroxyl ion(NO " ) .
- the reactive form of nitric oxide can be provided by gaseous nitric oxide.
- nitric oxide releasing, delivering or transferring compounds having the structure X-NO wherein X is a nitric oxide releasing, delivering or transferring moiety, include any and all such compounds which provide nitric oxide to its intended site of action in a form active for their intended purpose.
- NO adducts encompasses any of such nitric oxide releasing, delivering or transferring compounds, including, for example, S-nitrosothiols, S-nitroso amino acids, S-nitroso-polypeptides, and nitrosoamines. It is contemplated that any or all of these "NO adducts can be mono or poly- nirosylated at a variety of naturally susceptible or artificially provided binding sites for nitric oxide,
- S-nitrosothiols which are compounds that include at least one -S-NO group.
- Such compounds include S-nitroso-polypeptides
- polypeptide includes proteins and also polyamino acids that do not possess an ascertained biological function, and derivatives thereof
- S- nitrosylated amino acids (including natural and synthetic amino acids and their stereoisomers and racemic mixtures and derivatives thereof)
- S-nitrosated hydrocarbon where the hydrocarbon can be a branched or unbranched, and saturated or unsaturated aliphatic hydrocarbon, or an aromatic hydrocarbon; S-nitroso hydrocarbons having one or more substituent groups in addition to the S-nitroso group; and heterocyclic compounds.
- S-nitrosothiols and the methods for preparing them are described in U.S. Patent Application No. 07/943,834, filed September 14, 1992, Oae et al . , Org. Prep. Proc. Int., 15(3) .165-198
- S-nitroso amino acids where the nitroso group is linked to a sulfur group of a sulfur-containing amino acid or derivative thereof.
- such compounds include the following: S-nitroso-N-acetylcysteine, S- nitroso-captopril, S-nitroso-homocysteine, S-nitroso-- cysteine and S-nitroso-glutathione.
- Suitable S-nitrosylated proteins include thiol- containing proteins (where the NO group is attached to one or more sulfur group on an amino acid or amino acid derivative thereof) from various functional classes including enzymes, such as tissue-type plasminogen activator(TPA) and cathepsin B; transport proteins, such as lipoproteins, heme proteins such as hemoglobin and serum albumin; and biologically protective proteins, such as the immunoglobulins and the cytokines.
- TPA tissue-type plasminogen activator
- cathepsin B transport proteins, such as lipoproteins, heme proteins such as hemoglobin and serum albumin
- biologically protective proteins such as the immunoglobulins and the cytokines.
- nitrosylated proteins are described in PCT Publ. Applic. No. WO 93/09806, published May 27, 1993. Examples include polynitrosylated albumin where multiple thiol or other nucleophilic centers in the protein are modified.
- S-nitrosothiols include those having the structures:
- x equals 2 to 20 and Y is selected from the group consisting of fluoro, alkoxy, cyano, carboxamido, C 3 -C 6 cycloalkyl, aralkoxy, C 2 -C 6 alkylsulfinyl, arylthio, C- L -C 8 alkylamino, C 2 -C 15 dialkylamino, hydroxy, carbamoyl, Ci-Cg N-alkylcarbamoyl, C 2 -C 15 N,N-dialkylcarbamoyl, amino, hydroxyl, carboxyl, hydrogen, nitro and aryl; wherein aryl includes benzyl, naphthyl, and anthracenyl groups .
- S-nitroso-ACE inhibitors S-nitroso- angiotensin converting enzyme inhibitors
- R is hydroxy, NH 2 , NHR 4 , NR 4 R 5 , or C. . -C- alkoxy, wherein R 4 and R 5 are C 1 -C 4 alkyl, or phenyl, or C- . -C 4 alkyl substituted by phenyl;
- R 1 is hydrogen, C x -C 7 alkyl, or C- . -C- alkyl substituted by phenyl, amino, guanidino, NHR 6 , NR 6 R 7 , wherein R 6 and R 7 are methyl or C- . -C 4 alkanoyl;
- R 2 is hydrogen, hydroxy, C x -C 4 alkoxy, phenoxy, or Ci- , alkyl;
- R 3 is hydrogen, Cj . -C 4 or Ci-C, alkyl substituted by phenyl,- m is 1 to 3; and n is 0 to 2.
- S-nitroso-ACE inhibitors include N- acetyl-S-nitroso-D-cysteinyl -L-proline, N-acetyl -S- nitroso-D, L-cysteinyl-L-proline, 1- [4-amino-2- (S- nitroso) mercaptomethyl butanoyl] -L-proline, l- [2- hexanoyl] -L-proline, 1- [5 -guanidino -2 - (S- nitroso)mercaptomethyl -pentanoyl] -L-proline, 1- [5-amino- 2 - (S-nitroso) mercaptomethyl -pentanoyl] -4-hydroxy-L- proline , 1- [5-guanidino-2 - ( S-nitroso) mercaptomethyl - pentanoyl] -4-hydroxy-L-proline, 1- [2-a
- S-nitroso-ACE inhibitors include those having structures (2-3) :
- A is ON-S -CH 2 -CH-C;
- R is selected from hydrogen, lower (C x -C 4 ) alkyl, benzyl, benzhydryl, and salt forming ion;
- R x and R 2 are independently selected from hydrogen, halogen, lower alkyl, lower alkoxy, halo substituted lower alkyl, nitro, and S0 2 NH 2 ;
- R 3 is hydrogen, lower alkyl, halo substituted lower alkyl, phenyl, benzyl, phenethyl, or cycloalkyl;
- R 4 is hydrogen, lower alkyl, halo substituted lower alkyl, hydroxy substituted lower alkyl, -(CH 2 )_-N (lower alkyl) 2 or -(CH 2 )--NH 2 and q is one, two, three or four. Additional suitable compounds include those having structures (4-11) :
- the S-nitroso-ACE inhibitors can be prepared by various methods of synthesis.
- Acids which may be used for this purpose include aqueous sulfuric, acetic and hydrochloric acids.
- Thiol precursors are prepared as described in the following: U.S. Pat. Nos. 4,046,889
- Such compounds include 0-nitroso-polypeptides(the term "polypeptide” includes proteins and also polyamino acids that do not possess an ascertained biological function, and derivatives thereof) ; O-nitrosylated amino acids (including natural and synthetic amino acids and their stereoisomers and racemic mixtures and derivatives thereof) ; O-nitrosated sugars; O-nitrosated-modified and unmodified oligonucleotides (preferably of at least 5, and more particularly 5-200, nucleotides) ; and an O-nitrosated hydrocarbon where the hydrocarbon can be a branched or unbranched, saturated or unsaturated aliphatic hydrocarbon, or an aromatic hydrocarbon; O-nitroso hydrocarbons having one or more substituent groups in addition to the O-nitroso group; and heterocyclic compounds.
- NO adducts Another group of such NO adducts is the nitrites which have an -0-NO group wherein R is a protein, polypeptide, amino acid, branched or unbranched and saturated or unsaturated alkyl, aryl or a heterocyclic.
- R is a protein, polypeptide, amino acid, branched or unbranched and saturated or unsaturated alkyl, aryl or a heterocyclic.
- a preferred example is the nitosylated form of isosorbide.
- Compounds in this group form S-nitrosothiol intermediates in vivo in the recipient human or other animal to be treated and can therefore include any structurally analogous precursor R-O-NO of the S-nitrosothiols described above.
- N-nitrosoamines which are compounds that include at least one -N-NO group.
- Such compounds include N-nitroso- polypeptides (the term "polypeptide” includes proteins and also polyamino acids that do not possess an ascertained biological function, and derivatives thereof) ; N-nitrosylated amino acids (including natural and synthetic amino acids and their stereoisomers and racemic mixtures) ; N-nitrosated sugars; N-nitrosated- modified and unmodified oligonucleotides (preferably of at least 5, and more particularly 5-200, nucleotides); and an N-nitrosated hydrocarbon where the hydrocarbon can be a branched or unbranched, and saturated or unsaturated aliphatic hydrocarbon, or an aromatic hydrocarbon; N- nitroso hydrocarbons having one or more substituent groups in addition to the N-nitroso group; and heterocyclic compounds.
- C-nitroso compounds that include at least one -C-NO group.
- Such compounds include C-nitroso-polypeptides (the term "polypeptide” includes proteins and also polyamino acids that do not possess an ascertained biological function, and derivatives thereof) ; C-nitrosylated amino acids (including natural and synthetic amino acids and their stereoisomers and racemic mixtures) ; C-nitrosated sugars; C-nitrosated-modified and unmodified oligonucleotides (preferably of at least 5, and more particularly 5-200, nucleotides) ; and a C-nitrosated hydrocarbon where the hydrocarbon can be a branched or unbranched, and saturated or unsaturated aliphatic hydrocarbon, or an aromatic hydrocarbon; C-nitroso hydrocarbons having one or more substituent groups in addition to the C-nitroso group; and heterocyclic compounds.
- polypeptides include proteins and also polyamino acids that do not possess an ascertained biological function, and derivatives thereof
- amino acids including natural and synthetic amino acids and their stereoisomers and racemic mixtures and derivatives thereof
- sugars modified and unmodified oligonucleotides (preferably of at least 5, and more particularly 5-200, nucleotides)
- hydrocarbon where the hydrocarbon can be a branched or unbranched, and saturated or unsaturated aliphatic hydrocarbon, or an aromatic hydrocarbon; hydrocarbons having one or more substituent groups; and heterocyclic compounds.
- a preferred example is nitroglycerin.
- R includes polypeptides(the term "polypeptide” includes proteins and also polyamino acids that do not possess an ascertained biological function, and derivatives thereof) ; amino acids (including natural and synthetic amino acids and their stereoisomers and racemic mixtures and derivatives thereof) ; sugars; modified and unmodified oligonucleotides (preferably of at least 5, and more particularly 5-200, nucleotides); and a hydrocarbon where the hydrocarbon can be a branched or unbranched, and saturated or unsaturated aliphatic hydrocarbon, or an aromatic hydrocarbon,- hydrocarbons having one or more substituent groups in addition to the A-nitroso group; and heterocyclic compounds.
- A is S, 0, or N, n and x are each integers independently selected from 1, 2 and 3, and M is a metal, preferably a transition metal.
- Preferred metals include iron, copper, manganese, cobalt, selenium and luthidium. Also contemplated are N- nitrosylated metal centers such as nitroprusside.
- R includes polypeptides (the term "polypeptide” includes proteins and also polyamino acids that do not possess an ascertained biological function, and derivatives thereof); amino acids(including natural and synthetic amino acids and their stereoisomers and racemic mixtures and derivatives thereof) ; sugars; modified and unmodified oligonucleotides (preferably of at least 5, and more particularly 5-200, nucleotides); and a hydrocarbon where the hydrocarbon can be a branched or unbranched, and saturated or unsaturated aliphatic hydrocarbon, or an aromatic hydrocarbon,- hydrocarbons having one or more substituent groups,- and heterocyclic compounds.
- R is preferably a nucleophilic (basic) moiety.
- M+ is a metal cation, such as, for example, a Group I metal cation.
- thionitrates which have the structure R-(S) x -N0 wherein x is an integer of at least 2.
- R is as described above for the S- nitrosothiols.
- dithiols wherein x is 2.
- Particularly preferred are those compounds where R is a polypeptide or hydrocarbon and a par or pairs of thiols are sufficiently structurally proximate, i.e. vicinal, that the pair of thiols will be reduced to a disulfide.
- Those compounds which form disulfide species release nitroxyl ion(NO " ) and uncharged nitric oxide(NO*).
- Those compounds where the thiol groups are not sufficiently close to form disulfide bridges generally only provide nitric oxide as the NO " form but not as the uncharged N0» form.
- Agents which stimulate endogenous NO synthesis are also suitable for use in accordance with the invention.
- Viruses whose replication may be inhibited or prevented by the compounds described hereinabove include retroviruse ⁇ such as human immunodeficiency virus (HIV) , human T-cell leukemia virus-1 (HTLV-l) , and simian immunodeficiency virus (SIV) .
- retroviruse ⁇ such as human immunodeficiency virus (HIV) , human T-cell leukemia virus-1 (HTLV-l) , and simian immunodeficiency virus (SIV) .
- these compounds can be employed in various therapeutic treatments, including: l) the incorporation of NO donors into creams, salves or lotions for the treatment of topical infections; 2) the use of inhaled nitric oxide and other NO donors for the treatment of lung infections; 3) the use of topical drops and creams for the treatment of mucocutaneous membrane infections, such as infections of the eye, mouth and genitourinary tract; and 4) oral or parenteral administration for systemic or localized infections.
- the nitric oxide When administered in vivo, the nitric oxide may be administered in combination with pharmaceutical carriers and in dosages described herein.
- viruses can both replicate (lytic phase) and also incorporate themselves into the genome (latency) .
- the virus When latent, the virus may serve as a protooncogene, thereby promoting cancer,- and it is also resistant to antiviral therapy. Thus, the establishment of latency prevents elimination of virus with antiviral therap .
- Another aspect of the invention is based on the discovery that nitric oxide synthase inhibitors activate latent retrovirus. This is the first demonstration of a mechanism for eradicating the latent state, i.e., once activated, the retrovirus can then be eliminated with antiviral therapy. Thus, this aspect of the present invention is directed to the use of nitric oxide synthase inhibitors as a means to eradicate latent virus.
- the invention provides a method for preventing or reversing retroviral latency in a cell, tissue or animal infected therewith which comprises administering thereto a nitric oxide synthase inhibitor in an amount sufficient to render the retrovirus replication-competent.
- this aspect of the invention provides a method for the treatment of a latent retrovirus infection in a cell, tissue or animal so- infected, which comprises administering thereto (i) a nitric oxide synthase inhibitor in an amount sufficient to render the retrovirus replication-competent and (ii) a replication inhibitory amount of an antiviral agent.
- this aspect of the invention provides a composition for the treatment of a latent retrovirus infection in a cell, tissue or animal so- infected, which comprises (i) a nitric oxide synthase inhibitor in an amount sufficient to render the retrovirus replication-competent and (ii) a replication inhibitory amount of an antiviral agent in a pharmaceutically acceptable carrier.
- Suitable nitric oxide synthase inhibitors include arginine derivatives such as N ⁇ monomethyl-L-arginine (NMA) , nitro-arginine, diphenylene iodonium and related iodonium derivatives, N-nitro-L-arginine methyl ester, N- methyl-L-arginine, N-amino-L-arginine, ornithine, N- imino-ethyl-L-ornithine and ornithine derivatives, N- nitro-L-arginine, methylene blue, heme binders, trifluoropiperazine, and calcinarin and other calmodulin binders, such as methotrexate.
- NMA N ⁇ monomethyl-L-arginine
- nitro-arginine diphenylene iodonium and related iodonium derivatives
- N-nitro-L-arginine methyl ester N- methyl-L-arg
- antiviral agent refers to any agent that inhibits, prevents, or destroys the growth or replication of a retrovirus.
- the antiviral agent can be a purine nucleoside analog such as acyclovir or didanosine.
- the antiviral agent can be a pyrimidine nucleoside analog such as zidovudine, trifluridine and zalcitabine.
- the antiviral agent can also be a chelating agent such as foscarnet sodium.
- the antiviral agent can be an intercalating agent.
- the antiviral agent can be an interferon, preferably an ⁇ r-interferon, a ⁇ - interferon or a ⁇ -interferon. Other known antiviral agents and those subsequently to be discovered are contemplated as within the scope of this term.
- Treatment of localized topical infection with the nitric oxide or nitric oxide releasing agent comprises contacting the surface so as to cause the surface to be coated with the nitric oxide or nitric oxide releasing agent.
- Coating may be accomplished using standard methods well known to those of ordinary skill in the art. For example, coating a surface with nitric oxide adducts can be achieved by bathing the surface in a solution containing the nitric oxide adduct.
- synthetic nitric oxide adducts may be coated onto an artificial surface such as a bandage or covering by a variety of chemical techniques which are well known in the art.
- Modes of administration include but are not limited to topical, transdermal, intramuscular, intraperitoneal, intravenous, vaginal, subcutaneous, intranasal, topical and oral routes.
- the compounds may be administered by any convenient route, for example by infusion or bolus injection by absorption through epithelial or mucocutaneous linings (e.g., oral mucosa, rectal and intestinal mucosa, etc.) and may be administered together with other biologically active agents.
- Principal approaches to therapeutic uses of the invention include topical administration to treat skin infections; topical administration to treat genital and oral lesions; topical administration to treat eye infections; topical or inhalation administration of NO/or SNAC to treat respiratory infections; and particularly intravenous administration to treat systemic infection.
- the compounds of this invention can be employed in combination with conventional excipients, i. e. , pharmaceutically acceptable organic or inorganic carrier substances suitable for parenteral application which do not deleteriously react with the active compounds.
- suitable pharmaceutically acceptable carriers include, but are not limited to, water, salt solutions, alcohol, vegetable oils, polyethylene glycols, gelatin, lactose, amylose, magnesium stearate, talc, silicic acid, viscous paraffin, perfume oil, fatty acid monoglycerides and diglycerides, petroethral fatty acid esters, hydroxymethylcellulose, polyvinylpyrrolidone, etc.
- the pharmaceutical preparations can be sterilized and if desired, mixed with auxiliary agents, e.g., lubricants, preservatives, stabilizers, wetting agents, emulsifiers, salts for influencing osmotic pressure, buffers, colorings, flavoring and/or aromatic substances and the like which do not deleteriously react with the active compounds.
- auxiliary agents e.g., lubricants, preservatives, stabilizers, wetting agents, emulsifiers, salts for influencing osmotic pressure, buffers, colorings, flavoring and/or aromatic substances and the like which do not deleteriously react with the active compounds.
- auxiliary agents e.g., lubricants, preservatives, stabilizers, wetting agents, emulsifiers, salts for influencing osmotic pressure, buffers, colorings, flavoring and/or aromatic substances and the like which do not deleteriously react with the active compounds.
- particularly suitable vehicles consist of solutions
- the composition can also contain minor amounts of wetting or emulsifying agents, or pH buffering agents.
- the composition can be a liquid solution, suspension, emulsion, tablet, pill, capsule, sustained release formulation, or powder.
- the composition can be formulated as a suppository, with traditional binders and carriers such as triglycerides.
- Oral formulations can include standard carriers such as pharmaceutical grades of mannitol, lactose, starch, magnesium stearate, sodium saccharine, cellulose, magnesium carbonate, etc.
- Various delivery systems are known and can be used to administer a therapeutic compound or composition of the invention, e.g., encapsulation in uposomes, microparticles, microcapsules and the like.
- the composition is formulated in accordance with routine procedures as a pharmaceutical composition adapted for intravenous administration to human beings.
- compositions for intravenous administration are solutions in sterile isotonic aqueous buffer.
- the composition may also include a solubilizing agent and a local anesthetic to ameliorate any pain at the site of the injection.
- the ingredients are supplied either separately or mixed together in unit dosage form, for example, as a drylyophilized powder or water free concentrate in a hermetically sealed container such as an ampoule or sachette indicating the quantity of active agent.
- the composition is to be administered by infusion, it can be dispensed with an infusion bottle containing sterile pharmaceutical grade water or saline.
- an ampoule of sterile water for injection or saline can be provided so that the ingredients may be mixed prior to administration.
- the therapeutics of the invention can be formulated as neutral or salt forms.
- Pharmaceutically acceptable salts include those formed with free amino groups such as those derived from hydrochloric, phosphoric, sulfuric, acetic, oxalic, tartaric acids, etc., and those formed with free carboxyl groups such as those derived from sodium, potassium, ammonium, calcium, ferric hydroxides, isopropylamine, triethylamine, 2-ethylamino ethanol, histidine, procaine, etc.
- terapéuticaally effective amount refers to the amount of the nitric oxide adduct which is effective to achieve its intended purpose. While individual needs vary, determination of optimal ranges for effective amounts of each nitric oxide adduct is within the skill of the art. Generally, the dosage required to provide an effective amount of the composition, and which can be adjusted by one of ordinary skill in the art will vary, depending on the age, health, physical condition, sex, weight, extent of disease of the recipient, frequency of treatment and the nature and scope of the disorder.
- the amount of the therapeutic of the invention which will be effective in the treatment of a particular disorder or condition will depend on the nature of the disorder or condition, and can be determined by standard clinical techniques. The precise dose to be employed in the formulation will also depend on the route of administration, and the seriousness of the disease or disorder, and should be decided according to the judgment of the practitioner and each patient's circumstances.
- suitable dosage ranges for intravenous administration are generally about 20-500 micrograms of active compound per kilogram body weight.
- Suitable dosage ranges for intranasai administration are generally about 0.01 pg/kg body weight to 1 mg/kg body weight.
- Effective doses may be extrapolated from dose-response curves derived from in vitro or animal model test systems and are in the same ranges or less than as described for the commercially available compounds in the Physician's Desk Reference, Medical Economics Company, Inc., Oradell, N.J. 1990.
- the invention also provides a pharmaceutical pack or kit comprising one or more containers filled with one or more of the ingredients of the pharmaceutical compositions of the invention.
- a pharmaceutical pack or kit comprising one or more containers filled with one or more of the ingredients of the pharmaceutical compositions of the invention.
- Associated with such container(s) can be a notice in the form prescribed by a governmental agency regulating the manufacture, use or sale of pharmaceuticals or biological products, which notice reflects approval by the agency of manufacture, use or sale for human administration.
- Peripheral blood mononuclear cells isolated from HIV-1 negative adult donors were stimulated for 48 hours with 10 ⁇ g/ml of PHA.
- the cells were then infected with HIV-l strain MN at an MOI of 0.1 for 1-2 hours at 37°C, washed three times and resuspended at 500,000 cells/ml in complete medium (RPMI 1640 10% fetal bovine serum) supplemented with 10 units/ml of IL-10 with or without various concentrations of SNAP, NAP, SNAC or NAC.
- the cells were then plated in 24 well plates with 2 ml of cells per well. After 4 days, the cells were split and refed with the same media in which they were originally resuspended. After 5-8 days in culture, cell supernatants were collected, and p24 antigen levels determined using the HIV-1 p24 Core Profile assay (NEN) as per the manufacturer's instructions.
- H9 cells were pelleted and infected with HIV-1 strain MN at an MOI of 0.1 for 1-2 hours at 37°C, washed three times, resuspended at a concentration of 100,000 cells/ml in complete medium supplemented with or without SNAP, NAP, SNOP or penicillamine, and plated in 24 well plates with 2 ml of cells per well. After 3 days, p24 antigen levels were measured in the H9 cell supematants using the method described above.
- U937 cells were pelleted and infected with HIV-1 strain MN at an MOI of 0.2 for 1-2 hours at 37°C, washed three times and then resuspended at 100,000 cells/ml in RPMI 1640 containing 10% FBS and 0.1 mM arginine with or without L-NMA. The cells were then plated in 24 well plates containing 2 ml of cells per well. Twice a week the cells were split and refed with the same media in which they were originally resuspended. After 8-14 days, p24 antigen levels were measured in the cell supematants using the method described above.
- Ul cells were resuspended at a concentration of 100,000 cells per ml in RPMI 1640 (GIBCO) containing 10% FBS and 0.1 mM arginine with or without TNF- ⁇ or L-NMA. The cells were then plated in 24 well plates containing 2 ml of cells per well. After 48-72 hours in culture, p24 antigen levels were measured in the cell supematants using the method described above.
- the effect of NO generating compounds on HIV-1 replication was determined by growing human peripheral blood mononuclear cells (PBMCs) infected with HIV-1 (MN strain) in the presence or absence of NO-generating compounds or control parent compounds which do not generate NO.
- PBMCs peripheral blood mononuclear cells
- MN strain HIV-1
- the extent of HIV-1 replication was determined 5 to 8 days after infection by measuring p24 antigen levels in the cell supe atants.
- Figures 1A-1D show that NO generating compounds inhibit HIV-1 replication in human peripheral blood mononuclear cells and in the chronically infected human T cell line H9.
- Figure LA shows results when human peripheral blood mononuclear cells (PBMCs) stimulated with PHA and IL-2 were infected with HIV-1, and then grown in the presence or absence of the NO generating compound S-nitroso-N- acetyl-penicillamine (SNAP) , or the parent compound N- acetyl-penicillamine (NAP) .
- PBMCs peripheral blood mononuclear cells
- SNAP S-nitroso-N- acetyl-penicillamine
- NAP N- acetyl-penicillamine
- the NO generating compound S-nitroso-N-acetyl- penicillamine (SNAP) but not the control parent compound N-acetyl-penicillamine (NAP) , inhibited HIV replication in PBMCs in a dose dependent manner.
- the data are expressed as the percent of control p24 levels. Since SNAP and NAP were diluted in ETOH, the effect of 0.2% ETOH (the concentration present in 200 uM SNAP and NAP cultures) was determined. The results represent the mean of 9 separate experiments ⁇ SEM for 100, 200, and 300 uM SNAP or NAP, and the mean of 2 separate experiments for 10, 50, 150 and 250 uM SNAP or NAP concentrations.
- Figure IB shows the results when the same experiment as shown in Figure 1A was performed using the NO- generating compound S-nitroso-N-acetyl-cysteine (SNAC) or the parent compound N-acetyl cysteine (NAC) . Similar effects were seen with the NO-generating compound S- nitroso-N-acetyl-cysteine (SNAC) and the control parent compound N-acetyl-cysteine (NAC) . The data are expressed as the mean of duplicate cultures.
- Figure 1C shows the results when H9 cells were grown in the presence or absence of the NO generating compound SNAP; and After three days in the culture, p24 levels in the cell supematants were measured by ELISA. Again, the NO donor SNAP inhibited HIV replication in a dose dependent fashion. The data are expressed as the mean of duplicate cultures and are repesentative of one of three experiments.
- Figure ID shows the results when the same experiment as shown in Figure 1C was performed using the NO generating compound S-nitroso-penicillamine (SNP) or the control compound penicillamine (P) . Similar results were seen with the NO donor S-nitroso-penicillamine (SNP) but not with the parent compound penicillamine (P) . The data are expressed as the mean of duplicate cultures.
- Figures 2A-2B show the effect of NO on PBMC proliferation.
- Figure 2A shows the results when human peripheral blood mononuclear cells stimulated with PHA and IL-2 were grown in the presence or absence of the NO-generating compound SNAP or the parent compound NAP.
- the effects of SNAP or NAP on PBMC proliferation were analyzed by tritiated thymidine uptake. Higher concentrations of SNAP (i.e. 200 uM-500 uM) inhibited PBMC proliferation, however, 50-150 uM SNAP did not inhibit PBMC proliferation and yet inhibited p24 antigen production (Figure 1A) . After 6 days in culture, [ 3 H] -thymidine uptake was measured.
- SNAP and NAP were diluted in ETOH and therefore, as a control, the effect of ETOH on PBMC proliferation was measured.
- concentrations of ETOH present in 100, 200, 300, and 400 uM SNAP or NAP were 0.1%, 0.2%, 0.3%, and 0.4% ETOH, respectively.
- Figure 2B shows the results when the same experiment as shown in Figure 2A was performed using the NO- generating compound S-nitroso-N-acetyl cysteine (SNAC) or the control compound N-acetyl cysteine (NAC) . After 6 days in culture the number of viable cells was determined by trypan blue staining. Concentrations of SNAC which inhibited HIV replication (Figure IB) had no effect on PBMC proliferation. Thus NO appears to have an inhibitory effect on HIV replication which is independent of its anti-proliferative effect.
- SNAC S-nitroso-N-acetyl cysteine
- NAC N-acetyl cysteine
- NO synthase (NOS) activity is difficult to demonstrate in human mononuclear cells, presumably because they express very low levels of NOS.
- inducible NOS(iNOS) expression and activity was evident in the U-937 human promonocytic cell line.
- Figures 3A-3B show that iNOS is expressed constitutively in U-937 cells.
- Figure 3A shows cDNA that was made from whole cell RNA from U-937 or from the control B cell line B-958 which is known to express iNOS. Samples to which reverse transcriptase was (+RT) or was not (-RT) added are indicated. Equal amounts of each sample were PCR amplified using primers specific for human iNOS. The markers on the left indicate the base pair size of OX DNA fragments generated from an Hae III digest. iNOS RNA expression was detected in U-937 cells by RT-PCR using human iNOS-specific primers. This RT-PCR product was sequenced and found to be identical to the human hepatic iNOS cDNA sequence.
- Figure 3B shows a western blot that was performed on whole cell lysates made from 0.5xl0 6 U-937 cells (U-937), the human B cell line BL-30, and rat macrophages stimulated with LPS (Rat) .
- INOS expression was detected using an affinity purified rabbit antiserum was raised against the C-terminal 20 amino acids of the rat isoform and recognizes both human and rat iNOS (Kobzik et al . 1993) .
- the rat isoform which shares 80% homology with the human isoform, runs slightly below the human isoform on polyacrylamide gels.
- NO production by U- 937 cells was detected by a photolysis/chemilumincesence assay.
- Figure 4A shows the results when U-937 cells were infected with HIV-l and then grown in the presence or absence of the NOS inhibitor L-NMA,- and After 8-10 days in culture, p24 levels in the cell supe atants were determined by ELISA. Inhibition of endogenous NO synthesis by L-NMA caused a small but statistically significant increase in p24 antigen levels, with maximal effects seen between 100-250 uM L-NMA. The L-NMA-induced increase in p24 levels was abrogated by the addition of excess L-arginine, the NOS substrate. Thus, both endogenously synthesized NO and exogenous NO appear to inhibit HIV replication. The data represent the mean of 5 duplicate cultures and are representative of three separate experiments.
- Figure 4B shows the results when the latently infected Ul cell line was grown in the presence or absence of L-NMA and TNFa. and after 2-3 days in culture p24 antigen levels were measured in the cell supematants by ELISA.
- L-NMA caused a dose dependent increase in p24 antigen levels with maximal effects seen at a concentration of lmM ( Figure 4B) .
- the L-NMA-induced increase in p24 levels was abrogated by excess L-arginine but not D-arginine.
- the actions of NO can be broadly classified as either cGMP dependent or independent. For example, much of the inhibitory effect of NO on platelets and smooth muscle is mediated by increases in cGMP levels due to activation of guanylate cyclase.
- Figure 5 shows the effect of cGMP on HIV replication.
- Peripheral blood mononuclear cells were infected with HIV-l and then grown in the presence or absence of SNAP, NAP or the cGMP analog 8-bromo-cGMP. After 5 days p24 antigen levels were measured in the cell supematants.
- activation of guanylate cyclase may be one of the mechanisms by which NO inhibits HIV replication since ImM 8-bromo-cGMP (a cGMP analog) caused a three-fold inhibition of HIV replication (Figure 5) ; however, other mechanisms may also be involved in the N0- induced inhibition of HIV replication since NO-generating compounds can decrease HIV replication 7 fold without significantly inhibiting cellular proliferation (150 uM) .
- the data represent the mean of duplicate cultures.
Abstract
A method for treating a retroviral infection in a cell, tissue or animal so-infected by administering a retrovirus replication inhibitory amount of nitric oxide or a nitric oxide-delivering, releasing or transferring compound. A method for preventing or reversing retroviral latency in a cell, tissue or animal by administering thereto a nitric oxide synthase inhibitor in an amount sufficient to render retrovirus replication-competent. A method for the treatment of a latent retrovirus infection in a cell, tissue or animal by administering (i) a nitric oxide synthase inhibitor or nitric oxide scavenger in an amount sufficient to render the retrovirus replication-competent and (ii) a replication inhibitory amount of an antiviral agent. A composition comprising (i) a nitric oxide synthase inhibitor or nitric oxide scavenger in an amount sufficient to render the retrovirus replication-competent and (ii) a replication inhibitory amount of an antiviral agent in a pharmaceutically acceptable carrier.
Description
INHIBITING RETROVIRAL REPLICATION
This invention relates to the field of inhibiting retroviral replication in vitro and in vivo and to the treatment in humans and other animals of active and latent retroviral infections.
The invention is based on the discovery by the inventors that nitric oxide and adducts thereof which are nitric oxide donors inhibit retroviral replication and provides a method for inhibiting the replication of a retrovirus by exposing the retrovirus to nitric oxide or a nitric oxide-releasing, donating or transferring substance.
Thus, in one aspect, the present invention provides a method for inhibiting retroviral replication in a retrovirally infected cell or tissue culture in vitro which comprises contacting said retrovirally infected cell or tissue culture with an amount of nitric oxide or a nitric oxide-delivering, releasing or transferring compound sufficient to inhibit retroviral replication in said retrovirally infected cell or tissue culture.
Another aspect of the invention provides a method for inhibiting retroviral replication in a retrovirally
-1- SUBST1TUTESHEET(RULE26)
infected animal which comprises administering to said retrovirally infected animal an amount of nitric oxide or a nitric oxide-delivering, releasing or transferring compound sufficient to inhibit retroviral replication in said retrovirally infected animal.
Another aspect of the invention provides a method for inhibiting retroviral replication in a retrovirally infected individual which comprises administering to said retrovirally infected individual an amount of nitric oxide or a nitric oxide-delivering, releasing or transferring compound sufficient to inhibit retroviral replication in said retrovirally infected individual.
Another aspect of the invention provides a method for inhibiting the reactivation of latent retrovirus in a retrovirally infected cell or tissue culture which comprises contacting said retrovirally infected cell or tissue culture with a retrovirus reactivation inhibiting amount of nitric oxide, or a nitric oxide releasing, donating, or transferring substance which may be used prophylactically to prevent reactivation of latent retrovirus. This is very useful in mitigating the dangers of sample handling for research, laboratory and hospital personnel.
Another aspect of the invention provides a method for inhibiting the reactivation of a latent retrovirus infection in an animal in need thereof which comprises administering to said animal in need thereof an amount of nitric oxide, or a nitric oxide releasing, donating, or transferring substance sufficient to inhibit reactivation of latent retrovirus in said animal.
Another aspect of the invention provides a method for inhibiting the reactivation of a latent retrovirus infection in an individual in need thereof which comprises administering to an individual in need thereof
an amount of nitric oxide, or a nitric oxide releasing, donating, or transferring substance sufficient to inhibit reactivation of latent retrovirus in said individual. This is very useful, for example, in an immunocompromised host in which reactivation at an inopportune time (e.g. when defenses are low due to chemotherapy) would cause significant morbidity.
The invention is further based on the discovery by the inventors that nitric oxide synthase inhibitors and nitric oxide scavengers activate latent retrovirus. This is the first demonstration of a mechanism for eradicating the latent state, i.e., once activated, the retrovirus can then be eliminated with antiviral therapy. Thus, this aspect of the present invention is directed to the use of nitric oxide synthase inhibitors as a means to eradicate latent virus.
Thus, another aspect of the invention provides a method for preventing or reversing retroviral latency in a retrovirally infected cell or tissue culture in vitro which comprises contacting a retrovirally infected cell or tissue culture in vitro with a nitric oxide synthase inhibitor or nitric oxide scavenger, such as hemoglobin, in an amount sufficient to render the latent retrovirus in the retrovirally infected cell or tissue culture replication-competent.
Another aspect of the invention provides a composition for the treatment of a latent retrovirus infection in an animal infected with a latent retrovirus infection which comprises (i) a nitric oxide synthase inhibitor or nitric oxide scavenger, such as hemoglobin, in an amount sufficient to render the retrovirus infecting said animal replication-competent and (ii) a retrovirus replication inhibitory amount of an antiviral agent in a pharmaceutically acceptable carrier.
Another aspect of the invention provides a method for the treatment of a latent retrovirus infection in an animal infected with a latent retrovirus infection which comprises administering thereto (i) a nitric oxide synthase inhibitor or nitric oxide scavenger, such as hemoglobin, in an amount sufficient to render the retrovirus infecting said animal replication-competent and (ii) a retroviral replication inhibitory amount of an antiviral agent.
Another aspect of the invention provides a composition for the treatment of a latent retrovirus infection in an individual infected with a latent retrovirus infection which comprises (i) a nitric oxide synthase inhibitor or nitric oxide scavenger, such as hemoglobin, in an amount sufficient to render the retrovirus infecting said individual replication- competent and (ii) a retrovirus replication inhibitory amount of an antiviral agent in a pharmaceutically acceptable carrier.
Another aspect of the invention provides a method for the treatment of a latent retrovirus infection in an individual infected with a latent retrovirus infection which comprises administering thereto (i) a nitric oxide synthase inhibitor or nitric oxide scavenger, such as hemoglobin, in an amount sufficient to render the retrovirus infecting said individual replication- competent and (ii) a retroviral replication inhibitory amount of an antiviral agent.
Retroviruses whose growth may be inhibited in accordance with the method of the present invention include, but are not limited to, human immunodeficiency virus (HIV) , human T-cell leukemia virus-1 (HTLV-1) and simian immunodeficiency virus (SIV) . The administration can be topical, by inhalation, oral, or parenteral. The treated infection can be localized or systemic.
Figures 1A-1D show that NO generating compounds inhibit HIV-1 replication in human peripheral blood mononuclear cells and in the chronically infected human T cell line H9:
Figure 1A shows results when human peripheral blood mononuclear cells (PBMCε) stimulated with PHA and IL-2 were infected with HIV-1, and then grown in the presence or absence of the NO generating compound S- nitroso-N-acetyl-penicillamine (SNAP) , or the parent compound N-acetyl-penicillamine (NAP) ; Figure
IB shows the results when the same experiment as shown in Figure 1A was performed using the NO-generating compound S-nitroso-N-acetyl-cysteine (SNAC) or the parent compound N-acetyl cysteine (NAC) ;
Figure 1C shows the results when H9 cells were grown in the presence or absence of the NO generating compound SNAP; and
Figure ID shows the results when the same experiment as shown in Figure 1C was performed using the NO generating compound S-nitroso-penicillamine (SNP) or the control compound penicillamine (P) .
Figures 2A-2B show the effect of NO on PBMC proliferation:
Figure 2A shows the results when human peripheral blood mononuclear cells are stimulated with PHA and IL-2 were grown in the presence or absence of the NO-generating compound SNAP or the parent compound NAP; and
Figure 2B shows the results when the same experiment as shown in Figure 2A was performed using the NO-generating compound S-nitroso-N-acetyl cysteine (SNAC) or the control compound N-acetyl cysteine (NAC) .
Figures 3A-3B show that iNOS is expressed constitutively in U-937 cells;
Figure 3A shows cDNA that was made from whole cell RNA from U-937 or from the control B cell line B-958 which is known to express iNOS; and
Figure 3B shows a western blot that was performed on whole cell lysates made from 0.5xl06 U-937 cells (U-937), the human B cell line BL-30, and rat macrophages stimulated with LPS (Rat) .
Figures 4A-4B show that endogenously produced NO inhibits HIV replication and HIV reactivation:
Figure 4A shows the results when U-937 cells were infected with HIV-1 and then grown in the presence or absence of the NOS inhibitor L-NMA; and Figure 4B shows the results when the latently infected Ul cell line was grown in the presence or absence of L-NMA and TNFCU.
Figure 5 shows the effect of cGMP on HIV replication. Peripheral blood mononuclear cells were infected with HIV-1 and then grown in the presence or absence of SNAP, NAP or the cGMP analog 8-bromo-cGMP.
Compounds contemplated for use in the invention are nitric oxide and compounds that release nitric oxide or otherwise directly or indirectly deliver or transfer nitric oxide to a site of its activity, such as on a cell membrane, in vivo. As used here, the term "nitric oxide" encompasses uncharged nitric oxide(N0«) and charged nitric oxide species, particularly including nitrosonium ion(NO+) and nitroxyl ion(NO") . The reactive form of nitric oxide can be provided by gaseous nitric oxide. The nitric oxide releasing, delivering or transferring compounds, having the structure X-NO wherein X is a nitric oxide releasing, delivering or transferring moiety, include any and all such compounds which provide nitric oxide to its intended site of action in a form active for their intended purpose. As used here, the term "NO adducts" encompasses any of such nitric oxide
releasing, delivering or transferring compounds, including, for example, S-nitrosothiols, S-nitroso amino acids, S-nitroso-polypeptides, and nitrosoamines. It is contemplated that any or all of these "NO adducts can be mono or poly- nirosylated at a variety of naturally susceptible or artificially provided binding sites for nitric oxide,
One group of such NO adducts is the S-nitrosothiols, which are compounds that include at least one -S-NO group. Such compounds include S-nitroso-polypeptides
(the term "polypeptide" includes proteins and also polyamino acids that do not possess an ascertained biological function, and derivatives thereof) ; S- nitrosylated amino acids(including natural and synthetic amino acids and their stereoisomers and racemic mixtures and derivatives thereof) ; S-nitrosated sugars, S- nitrosated-modified and unmodified oligonucleotides
(preferably of at least 5, and more particularly 5-200, nucleotides) ; and an S-nitrosated hydrocarbon where the hydrocarbon can be a branched or unbranched, and saturated or unsaturated aliphatic hydrocarbon, or an aromatic hydrocarbon; S-nitroso hydrocarbons having one or more substituent groups in addition to the S-nitroso group; and heterocyclic compounds. S-nitrosothiols and the methods for preparing them are described in U.S. Patent Application No. 07/943,834, filed September 14, 1992, Oae et al . , Org. Prep. Proc. Int., 15(3) .165-198
(1983); Loscalzo et al . , J. Pharmacol. Exp. Ther., 249(3) .726729 (1989) and Kowaluk et al., J. Pharmacol. Exp. Ther., 256:1256-1264 (1990), all of which are incorporated in their entirety by reference.
One particularly preferred embodiment of this aspect relates to S-nitroso amino acids where the nitroso group is linked to a sulfur group of a sulfur-containing amino acid or derivative thereof. For example, such compounds include the following: S-nitroso-N-acetylcysteine, S-
nitroso-captopril, S-nitroso-homocysteine, S-nitroso-- cysteine and S-nitroso-glutathione.
Suitable S-nitrosylated proteins include thiol- containing proteins (where the NO group is attached to one or more sulfur group on an amino acid or amino acid derivative thereof) from various functional classes including enzymes, such as tissue-type plasminogen activator(TPA) and cathepsin B; transport proteins, such as lipoproteins, heme proteins such as hemoglobin and serum albumin; and biologically protective proteins, such as the immunoglobulins and the cytokines. Such nitrosylated proteins are described in PCT Publ. Applic. No. WO 93/09806, published May 27, 1993. Examples include polynitrosylated albumin where multiple thiol or other nucleophilic centers in the protein are modified.
Further examples of suitable S-nitrosothiols include those having the structures:
(i) CH3(CH_)_SNO wherein x equals 2 to 20;
(ii) HS(CH2)_SNO wherein x equals 2 to 20; and
(iii) ONS(CH2)_Y wherein x equals 2 to 20 and Y is selected from the group consisting of fluoro,
alkoxy, cyano, carboxamido, C3-C6 cycloalkyl, aralkoxy, C2-C6 alkylsulfinyl, arylthio, C-L-C8 alkylamino, C2-C15 dialkylamino, hydroxy, carbamoyl, Ci-Cg N-alkylcarbamoyl, C2-C15 N,N-dialkylcarbamoyl, amino, hydroxyl, carboxyl, hydrogen, nitro and aryl; wherein aryl includes benzyl, naphthyl, and anthracenyl groups .
Other suitable S-nitrosothiols that are S-nitroso- angiotensin converting enzyme inhibitors (hereinafter referred to as S-nitroso-ACE inhibitors) are described in Loscalzo, U.S. Patent No. 5,002,964 (1991) and Loscalzo
et al., U.S. Patent No. 5,025,001 (1991) both of which are incorporated in their entirety by reference. Examples of such S-nitroso-ACE inhibitors include compounds having structure (1) :
ON—«—( fC>Hfc— ?C■H— ? C—N*"τCH* ?C—«
(1)
wherein
R is hydroxy, NH2, NHR4, NR4R5, or C..-C- alkoxy, wherein R4 and R5 are C1-C4 alkyl, or phenyl, or C-.-C4 alkyl substituted by phenyl;
R1 is hydrogen, Cx-C7 alkyl, or C-.-C- alkyl substituted by phenyl, amino, guanidino, NHR6, NR6R7, wherein R6 and R7 are methyl or C-.-C4 alkanoyl;
R2 is hydrogen, hydroxy, Cx-C4 alkoxy, phenoxy, or Ci- , alkyl;
R3 is hydrogen, Cj.-C4 or Ci-C, alkyl substituted by phenyl,- m is 1 to 3; and n is 0 to 2.
Other suitable S-nitroso-ACE inhibitors include N- acetyl-S-nitroso-D-cysteinyl -L-proline, N-acetyl -S- nitroso-D, L-cysteinyl-L-proline, 1- [4-amino-2- (S- nitroso) mercaptomethyl butanoyl] -L-proline, l- [2- hexanoyl] -L-proline, 1- [5 -guanidino -2 - (S- nitroso)mercaptomethyl -pentanoyl] -L-proline, 1- [5-amino- 2 - (S-nitroso) mercaptomethyl -pentanoyl] -4-hydroxy-L- proline , 1- [5-guanidino-2 - ( S-nitroso) mercaptomethyl - pentanoyl] -4-hydroxy-L-proline, 1- [2-aminomethyl-3 (S-
nitroso) -mercaptomethyl-pentanoyl-L-proline, and S- nitroso-L-cysteinyl-L-proline.
Additional suitable S-nitroso-ACE inhibitors include those having structures (2-3) :
wherein
X is oxygen or sulfur; -A! , -A2- is CH-NH or -C=N- ;
R3 0 I !f
A is ON-S -CH2-CH-C;
R is selected from hydrogen, lower (Cx-C4) alkyl, benzyl, benzhydryl, and salt forming ion;
Rx and R2 are independently selected from hydrogen, halogen, lower alkyl, lower alkoxy, halo substituted lower alkyl, nitro, and S02NH2;
R3 is hydrogen, lower alkyl, halo substituted lower alkyl, phenyl, benzyl, phenethyl, or cycloalkyl; and
R4 is hydrogen, lower alkyl, halo substituted lower alkyl, hydroxy substituted lower alkyl, -(CH2)_-N (lower alkyl)2 or -(CH2)--NH2 and q is one, two, three or four.
Additional suitable compounds include those having structures (4-11) :
The S-nitroso-ACE inhibitors can be prepared by various methods of synthesis. In general, the thiol precursor is prepared first, then converted to the S- nitrosothiol derivative by nitrosation of the thiol group with NaN02 under acidic conditions (pH = 1 to 5) which yields the S-nitroso derivative. Acids which may be used
for this purpose include aqueous sulfuric, acetic and hydrochloric acids. Thiol precursors are prepared as described in the following: U.S. Pat. Nos. 4,046,889
(1977); 4,052,511; 4,053,651; 4,113,751, 4,154,840, 4129,571 (1978), and 4,154,960 (1979) to Ondetti et al.; U.S. Pat. No. 4,626,545 (1986) to Taub; and U.S. Pat. Nos. 4,692,458 (1987) and 4,692,459 (1987) to Ryan et al . , Quadro, U.S. Pat. No. 4,447,419 (1984); Haugwitz et al . ; U.S. Pat. No. 4,681,886 (1987), Bush et al., U.S. Pat. No. 4,568,675 (1986), Bennion et al . , U.S. Pat. No. 4,748,160 (1988), Portlock, U.S. Pat. No. 4,461,896
(1984), Hoefle et al . , European Patent Application Publication No. 0 088 341 (1983), Huange et al . , U.S. Pat. No. 4,585,758 (1986), European Patent application Publication No. 0 237 239, European Patent application Publication No. 0 174 162, published in 1986, European Patent application Publication No. 0 257 485, published in 1988, all of which are incorporated by reference herein.
Another group of such NO adducts are compounds that include at least one -O-NO group. Such compounds include 0-nitroso-polypeptides(the term "polypeptide" includes proteins and also polyamino acids that do not possess an ascertained biological function, and derivatives thereof) ; O-nitrosylated amino acids (including natural and synthetic amino acids and their stereoisomers and racemic mixtures and derivatives thereof) ; O-nitrosated sugars; O-nitrosated-modified and unmodified oligonucleotides (preferably of at least 5, and more particularly 5-200, nucleotides) ; and an O-nitrosated hydrocarbon where the hydrocarbon can be a branched or unbranched, saturated or unsaturated aliphatic hydrocarbon, or an aromatic hydrocarbon; O-nitroso hydrocarbons having one or more substituent groups in addition to the O-nitroso group; and heterocyclic compounds.
Another group of such NO adducts is the nitrites which have an -0-NO group wherein R is a protein, polypeptide, amino acid, branched or unbranched and saturated or unsaturated alkyl, aryl or a heterocyclic. A preferred example is the nitosylated form of isosorbide. Compounds in this group form S-nitrosothiol intermediates in vivo in the recipient human or other animal to be treated and can therefore include any structurally analogous precursor R-O-NO of the S-nitrosothiols described above.
Another group of such NO adducts is the N- nitrosoamines, which are compounds that include at least one -N-NO group. Such compounds include N-nitroso- polypeptides (the term "polypeptide" includes proteins and also polyamino acids that do not possess an ascertained biological function, and derivatives thereof) ; N-nitrosylated amino acids (including natural and synthetic amino acids and their stereoisomers and racemic mixtures) ; N-nitrosated sugars; N-nitrosated- modified and unmodified oligonucleotides (preferably of at least 5, and more particularly 5-200, nucleotides); and an N-nitrosated hydrocarbon where the hydrocarbon can be a branched or unbranched, and saturated or unsaturated aliphatic hydrocarbon, or an aromatic hydrocarbon; N- nitroso hydrocarbons having one or more substituent groups in addition to the N-nitroso group; and heterocyclic compounds.
Another group of such NO adducts is the C-nitroso compounds that include at least one -C-NO group. Such compounds include C-nitroso-polypeptides (the term "polypeptide" includes proteins and also polyamino acids that do not possess an ascertained biological function, and derivatives thereof) ; C-nitrosylated amino acids (including natural and synthetic amino acids and their stereoisomers and racemic mixtures) ; C-nitrosated sugars; C-nitrosated-modified and unmodified oligonucleotides
(preferably of at least 5, and more particularly 5-200, nucleotides) ; and a C-nitrosated hydrocarbon where the hydrocarbon can be a branched or unbranched, and saturated or unsaturated aliphatic hydrocarbon, or an aromatic hydrocarbon; C-nitroso hydrocarbons having one or more substituent groups in addition to the C-nitroso group; and heterocyclic compounds.
Another group of such NO adducts is the nitrates which have at least one -0-N02 group. Such compounds include polypeptides (the term "polypeptide" includes proteins and also polyamino acids that do not possess an ascertained biological function, and derivatives thereof) ; amino acids (including natural and synthetic amino acids and their stereoisomers and racemic mixtures and derivatives thereof) ; sugars; modified and unmodified oligonucleotides (preferably of at least 5, and more particularly 5-200, nucleotides) ; and a hydrocarbon where the hydrocarbon can be a branched or unbranched, and saturated or unsaturated aliphatic hydrocarbon, or an aromatic hydrocarbon; hydrocarbons having one or more substituent groups; and heterocyclic compounds. A preferred example is nitroglycerin.
Another group of such NO adducts is the nitroso- metal compounds which have the structure (R)n-A-M- (NO)x. R includes polypeptides(the term "polypeptide" includes proteins and also polyamino acids that do not possess an ascertained biological function, and derivatives thereof) ; amino acids (including natural and synthetic amino acids and their stereoisomers and racemic mixtures and derivatives thereof) ; sugars; modified and unmodified oligonucleotides (preferably of at least 5, and more particularly 5-200, nucleotides); and a hydrocarbon where the hydrocarbon can be a branched or unbranched, and saturated or unsaturated aliphatic hydrocarbon, or an aromatic hydrocarbon,- hydrocarbons having one or more substituent groups in addition to the A-nitroso group;
and heterocyclic compounds. A is S, 0, or N, n and x are each integers independently selected from 1, 2 and 3, and M is a metal, preferably a transition metal. Preferred metals include iron, copper, manganese, cobalt, selenium and luthidium. Also contemplated are N- nitrosylated metal centers such as nitroprusside.
Another group of such NO adducts is the N-oxo-N- nitrosoamines which have an R-N(0"M+) -NO group or an R- NO-NO-group. R includes polypeptides (the term "polypeptide" includes proteins and also polyamino acids that do not possess an ascertained biological function, and derivatives thereof); amino acids(including natural and synthetic amino acids and their stereoisomers and racemic mixtures and derivatives thereof) ; sugars; modified and unmodified oligonucleotides (preferably of at least 5, and more particularly 5-200, nucleotides); and a hydrocarbon where the hydrocarbon can be a branched or unbranched, and saturated or unsaturated aliphatic hydrocarbon, or an aromatic hydrocarbon,- hydrocarbons having one or more substituent groups,- and heterocyclic compounds. R is preferably a nucleophilic (basic) moiety. M+ is a metal cation, such as, for example, a Group I metal cation.
Another group of such NO adducts is the thionitrates which have the structure R-(S)x-N0 wherein x is an integer of at least 2. R is as described above for the S- nitrosothiols. Preferred are the dithiols wherein x is 2. Particularly preferred are those compounds where R is a polypeptide or hydrocarbon and a par or pairs of thiols are sufficiently structurally proximate, i.e. vicinal, that the pair of thiols will be reduced to a disulfide. Those compounds which form disulfide species release nitroxyl ion(NO") and uncharged nitric oxide(NO*). Those compounds where the thiol groups are not sufficiently close to form disulfide bridges generally only provide nitric oxide as the NO" form but not as the uncharged N0» form.
Agents which stimulate endogenous NO synthesis are also suitable for use in accordance with the invention.
Viruses whose replication may be inhibited or prevented by the compounds described hereinabove include retroviruseε such as human immunodeficiency virus (HIV) , human T-cell leukemia virus-1 (HTLV-l) , and simian immunodeficiency virus (SIV) . Thus, these compounds can be employed in various therapeutic treatments, including: l) the incorporation of NO donors into creams, salves or lotions for the treatment of topical infections; 2) the use of inhaled nitric oxide and other NO donors for the treatment of lung infections; 3) the use of topical drops and creams for the treatment of mucocutaneous membrane infections, such as infections of the eye, mouth and genitourinary tract; and 4) oral or parenteral administration for systemic or localized infections.
When administered in vivo, the nitric oxide may be administered in combination with pharmaceutical carriers and in dosages described herein.
Certain viruses can both replicate (lytic phase) and also incorporate themselves into the genome (latency) . One associates infectious disease with the replicative cycle of the virus,- however, significant morbidity may be associated with the latent phase as well. Further, certain viruses tend to establish latency more readily than others. When latent, the virus may serve as a protooncogene, thereby promoting cancer,- and it is also resistant to antiviral therapy. Thus, the establishment of latency prevents elimination of virus with antiviral therap .
Another aspect of the invention is based on the discovery that nitric oxide synthase inhibitors activate latent retrovirus. This is the first demonstration of a mechanism for eradicating the latent state, i.e., once
activated, the retrovirus can then be eliminated with antiviral therapy. Thus, this aspect of the present invention is directed to the use of nitric oxide synthase inhibitors as a means to eradicate latent virus.
Thus, in one embodiment of this aspect, the invention provides a method for preventing or reversing retroviral latency in a cell, tissue or animal infected therewith which comprises administering thereto a nitric oxide synthase inhibitor in an amount sufficient to render the retrovirus replication-competent.
In another embodiment, this aspect of the invention provides a method for the treatment of a latent retrovirus infection in a cell, tissue or animal so- infected, which comprises administering thereto (i) a nitric oxide synthase inhibitor in an amount sufficient to render the retrovirus replication-competent and (ii) a replication inhibitory amount of an antiviral agent.
In another embodiment, this aspect of the invention provides a composition for the treatment of a latent retrovirus infection in a cell, tissue or animal so- infected, which comprises (i) a nitric oxide synthase inhibitor in an amount sufficient to render the retrovirus replication-competent and (ii) a replication inhibitory amount of an antiviral agent in a pharmaceutically acceptable carrier.
Suitable nitric oxide synthase inhibitors include arginine derivatives such as N^monomethyl-L-arginine (NMA) , nitro-arginine, diphenylene iodonium and related iodonium derivatives, N-nitro-L-arginine methyl ester, N- methyl-L-arginine, N-amino-L-arginine, ornithine, N- imino-ethyl-L-ornithine and ornithine derivatives, N- nitro-L-arginine, methylene blue, heme binders, trifluoropiperazine, and calcinarin and other calmodulin binders, such as methotrexate.
The term "antiviral agent," refers to any agent that inhibits, prevents, or destroys the growth or replication of a retrovirus. The antiviral agent can be a purine nucleoside analog such as acyclovir or didanosine. Alternatively, the antiviral agent can be a a pyrimidine nucleoside analog such as zidovudine, trifluridine and zalcitabine. The antiviral agent can also be a chelating agent such as foscarnet sodium. The antiviral agent can be an intercalating agent. Further, the antiviral agent can be an interferon, preferably an αr-interferon, a β- interferon or a γ-interferon. Other known antiviral agents and those subsequently to be discovered are contemplated as within the scope of this term.
Treatment of localized topical infection with the nitric oxide or nitric oxide releasing agent comprises contacting the surface so as to cause the surface to be coated with the nitric oxide or nitric oxide releasing agent. Coating may be accomplished using standard methods well known to those of ordinary skill in the art. For example, coating a surface with nitric oxide adducts can be achieved by bathing the surface in a solution containing the nitric oxide adduct. In addition, synthetic nitric oxide adducts may be coated onto an artificial surface such as a bandage or covering by a variety of chemical techniques which are well known in the art.
Modes of administration include but are not limited to topical, transdermal, intramuscular, intraperitoneal, intravenous, vaginal, subcutaneous, intranasal, topical and oral routes. The compounds may be administered by any convenient route, for example by infusion or bolus injection by absorption through epithelial or mucocutaneous linings (e.g., oral mucosa, rectal and intestinal mucosa, etc.) and may be administered together with other biologically active agents.
Principal approaches to therapeutic uses of the invention include topical administration to treat skin infections; topical administration to treat genital and oral lesions; topical administration to treat eye infections; topical or inhalation administration of NO/or SNAC to treat respiratory infections; and particularly intravenous administration to treat systemic infection.
The compounds of this invention can be employed in combination with conventional excipients, i. e. , pharmaceutically acceptable organic or inorganic carrier substances suitable for parenteral application which do not deleteriously react with the active compounds. Suitable pharmaceutically acceptable carriers include, but are not limited to, water, salt solutions, alcohol, vegetable oils, polyethylene glycols, gelatin, lactose, amylose, magnesium stearate, talc, silicic acid, viscous paraffin, perfume oil, fatty acid monoglycerides and diglycerides, petroethral fatty acid esters, hydroxymethylcellulose, polyvinylpyrrolidone, etc. The pharmaceutical preparations can be sterilized and if desired, mixed with auxiliary agents, e.g., lubricants, preservatives, stabilizers, wetting agents, emulsifiers, salts for influencing osmotic pressure, buffers, colorings, flavoring and/or aromatic substances and the like which do not deleteriously react with the active compounds. For parenteral application, particularly suitable vehicles consist of solutions, preferably oily or aqueous solutions, as well as suspensions, emulsions, or implants. Aqueous suspensions may contain substances which increase the viscosity of the suspension and include, for example, sodium carboxymethyl cellulose, sorbitol, and/or dextran. Optionally, the suspension may also contain stabilizers.
The composition, if desired, can also contain minor amounts of wetting or emulsifying agents, or pH buffering agents. The composition can be a liquid solution,
suspension, emulsion, tablet, pill, capsule, sustained release formulation, or powder. The composition can be formulated as a suppository, with traditional binders and carriers such as triglycerides. Oral formulations can include standard carriers such as pharmaceutical grades of mannitol, lactose, starch, magnesium stearate, sodium saccharine, cellulose, magnesium carbonate, etc.
Various delivery systems are known and can be used to administer a therapeutic compound or composition of the invention, e.g., encapsulation in uposomes, microparticles, microcapsules and the like.
In a preferred embodiment, the composition is formulated in accordance with routine procedures as a pharmaceutical composition adapted for intravenous administration to human beings. Typically, compositions for intravenous administration are solutions in sterile isotonic aqueous buffer. Where necessary, the composition may also include a solubilizing agent and a local anesthetic to ameliorate any pain at the site of the injection. Generally, the ingredients are supplied either separately or mixed together in unit dosage form, for example, as a drylyophilized powder or water free concentrate in a hermetically sealed container such as an ampoule or sachette indicating the quantity of active agent. Where the composition is to be administered by infusion, it can be dispensed with an infusion bottle containing sterile pharmaceutical grade water or saline. Where the composition is administered by injection, an ampoule of sterile water for injection or saline can be provided so that the ingredients may be mixed prior to administration.
The therapeutics of the invention can be formulated as neutral or salt forms. Pharmaceutically acceptable salts include those formed with free amino groups such as those derived from hydrochloric, phosphoric, sulfuric,
acetic, oxalic, tartaric acids, etc., and those formed with free carboxyl groups such as those derived from sodium, potassium, ammonium, calcium, ferric hydroxides, isopropylamine, triethylamine, 2-ethylamino ethanol, histidine, procaine, etc.
The term "therapeutically effective amount," for the purposes of the invention, refers to the amount of the nitric oxide adduct which is effective to achieve its intended purpose. While individual needs vary, determination of optimal ranges for effective amounts of each nitric oxide adduct is within the skill of the art. Generally, the dosage required to provide an effective amount of the composition, and which can be adjusted by one of ordinary skill in the art will vary, depending on the age, health, physical condition, sex, weight, extent of disease of the recipient, frequency of treatment and the nature and scope of the disorder.
The amount of the therapeutic of the invention which will be effective in the treatment of a particular disorder or condition will depend on the nature of the disorder or condition, and can be determined by standard clinical techniques. The precise dose to be employed in the formulation will also depend on the route of administration, and the seriousness of the disease or disorder, and should be decided according to the judgment of the practitioner and each patient's circumstances. However, suitable dosage ranges for intravenous administration are generally about 20-500 micrograms of active compound per kilogram body weight. Suitable dosage ranges for intranasai administration are generally about 0.01 pg/kg body weight to 1 mg/kg body weight. Effective doses may be extrapolated from dose-response curves derived from in vitro or animal model test systems and are in the same ranges or less than as described for the commercially available compounds in the Physician's
Desk Reference, Medical Economics Company, Inc., Oradell, N.J. 1990.
The invention also provides a pharmaceutical pack or kit comprising one or more containers filled with one or more of the ingredients of the pharmaceutical compositions of the invention. Associated with such container(s) can be a notice in the form prescribed by a governmental agency regulating the manufacture, use or sale of pharmaceuticals or biological products, which notice reflects approval by the agency of manufacture, use or sale for human administration.
The following non-limitative examples further describe and enable one of ordinary skill in the art to make and use the invention.
EXAMPLE 1
In this example, the following materials were employed and experimental procedures were followed:
Infection of Peripheral Blood Mononuclear Cells
Peripheral blood mononuclear cells isolated from HIV-1 negative adult donors were stimulated for 48 hours with 10 μg/ml of PHA. The cells were then infected with HIV-l strain MN at an MOI of 0.1 for 1-2 hours at 37°C, washed three times and resuspended at 500,000 cells/ml in complete medium (RPMI 1640 10% fetal bovine serum) supplemented with 10 units/ml of IL-10 with or without various concentrations of SNAP, NAP, SNAC or NAC. The cells were then plated in 24 well plates with 2 ml of cells per well. After 4 days, the cells were split and refed with the same media in which they were originally resuspended. After 5-8 days in culture, cell supernatants were collected, and p24 antigen levels
determined using the HIV-1 p24 Core Profile assay (NEN) as per the manufacturer's instructions.
Infection of H9 cells
H9 cells were pelleted and infected with HIV-1 strain MN at an MOI of 0.1 for 1-2 hours at 37°C, washed three times, resuspended at a concentration of 100,000 cells/ml in complete medium supplemented with or without SNAP, NAP, SNOP or penicillamine, and plated in 24 well plates with 2 ml of cells per well. After 3 days, p24 antigen levels were measured in the H9 cell supematants using the method described above.
Infection of U937 cells
U937 cells were pelleted and infected with HIV-1 strain MN at an MOI of 0.2 for 1-2 hours at 37°C, washed three times and then resuspended at 100,000 cells/ml in RPMI 1640 containing 10% FBS and 0.1 mM arginine with or without L-NMA. The cells were then plated in 24 well plates containing 2 ml of cells per well. Twice a week the cells were split and refed with the same media in which they were originally resuspended. After 8-14 days, p24 antigen levels were measured in the cell supematants using the method described above.
Reactivation of virus from Ul cells
Ul cells were resuspended at a concentration of 100,000 cells per ml in RPMI 1640 (GIBCO) containing 10% FBS and 0.1 mM arginine with or without TNF-α or L-NMA. The cells were then plated in 24 well plates containing 2 ml of cells per well. After 48-72 hours in culture, p24 antigen levels were measured in the cell supematants using the method described above.
The effect of NO generating compounds on HIV-1 replication was determined by growing human peripheral blood mononuclear cells (PBMCs) infected with HIV-1 (MN strain) in the presence or absence of NO-generating
compounds or control parent compounds which do not generate NO. The extent of HIV-1 replication was determined 5 to 8 days after infection by measuring p24 antigen levels in the cell supe atants.
Figures 1A-1D show that NO generating compounds inhibit HIV-1 replication in human peripheral blood mononuclear cells and in the chronically infected human T cell line H9.
Figure LA shows results when human peripheral blood mononuclear cells (PBMCs) stimulated with PHA and IL-2 were infected with HIV-1, and then grown in the presence or absence of the NO generating compound S-nitroso-N- acetyl-penicillamine (SNAP) , or the parent compound N- acetyl-penicillamine (NAP) . P24 levels were measured in the cell supe atants by ELISA 6 days after infection. As a control, cells were infected in the absence of added drug. The NO generating compound S-nitroso-N-acetyl- penicillamine (SNAP) , but not the control parent compound N-acetyl-penicillamine (NAP) , inhibited HIV replication in PBMCs in a dose dependent manner. The data are expressed as the percent of control p24 levels. Since SNAP and NAP were diluted in ETOH, the effect of 0.2% ETOH (the concentration present in 200 uM SNAP and NAP cultures) was determined. The results represent the mean of 9 separate experiments ± SEM for 100, 200, and 300 uM SNAP or NAP, and the mean of 2 separate experiments for 10, 50, 150 and 250 uM SNAP or NAP concentrations.
Figure IB shows the results when the same experiment as shown in Figure 1A was performed using the NO- generating compound S-nitroso-N-acetyl-cysteine (SNAC) or the parent compound N-acetyl cysteine (NAC) . Similar effects were seen with the NO-generating compound S- nitroso-N-acetyl-cysteine (SNAC) and the control parent compound N-acetyl-cysteine (NAC) . The data are expressed as the mean of duplicate cultures.
Figure 1C shows the results when H9 cells were grown in the presence or absence of the NO generating compound SNAP; and After three days in the culture, p24 levels in the cell supematants were measured by ELISA. Again, the NO donor SNAP inhibited HIV replication in a dose dependent fashion. The data are expressed as the mean of duplicate cultures and are repesentative of one of three experiments.
Figure ID shows the results when the same experiment as shown in Figure 1C was performed using the NO generating compound S-nitroso-penicillamine (SNP) or the control compound penicillamine (P) . Similar results were seen with the NO donor S-nitroso-penicillamine (SNP) but not with the parent compound penicillamine (P) . The data are expressed as the mean of duplicate cultures.
Since NO inhibits lymphocyte proliferation and inhibition of cellular proliferation is associated with an inhibition of HIV replication, we determined whether the SNAP-induced inhibition of HIV replication was due simply to an anti-proliferative effect of the compound. Figures 2A-2B show the effect of NO on PBMC proliferation.
Figure 2A shows the results when human peripheral blood mononuclear cells stimulated with PHA and IL-2 were grown in the presence or absence of the NO-generating compound SNAP or the parent compound NAP. The effects of SNAP or NAP on PBMC proliferation were analyzed by tritiated thymidine uptake. Higher concentrations of SNAP (i.e. 200 uM-500 uM) inhibited PBMC proliferation, however, 50-150 uM SNAP did not inhibit PBMC proliferation and yet inhibited p24 antigen production (Figure 1A) . After 6 days in culture, [3H] -thymidine uptake was measured. SNAP and NAP were diluted in ETOH and therefore, as a control, the effect of ETOH on PBMC proliferation was measured. The concentrations of ETOH
present in 100, 200, 300, and 400 uM SNAP or NAP were 0.1%, 0.2%, 0.3%, and 0.4% ETOH, respectively.
Figure 2B shows the results when the same experiment as shown in Figure 2A was performed using the NO- generating compound S-nitroso-N-acetyl cysteine (SNAC) or the control compound N-acetyl cysteine (NAC) . After 6 days in culture the number of viable cells was determined by trypan blue staining. Concentrations of SNAC which inhibited HIV replication (Figure IB) had no effect on PBMC proliferation. Thus NO appears to have an inhibitory effect on HIV replication which is independent of its anti-proliferative effect.
Since NO generating compounds inhibit HIV-l replication, the effect of endogenously synthesized NO on HIV-l replication was analyzed. NO synthase (NOS) activity is difficult to demonstrate in human mononuclear cells, presumably because they express very low levels of NOS. However, inducible NOS(iNOS) expression and activity was evident in the U-937 human promonocytic cell line. Figures 3A-3B show that iNOS is expressed constitutively in U-937 cells.
Figure 3A shows cDNA that was made from whole cell RNA from U-937 or from the control B cell line B-958 which is known to express iNOS. Samples to which reverse transcriptase was (+RT) or was not (-RT) added are indicated. Equal amounts of each sample were PCR amplified using primers specific for human iNOS. The markers on the left indicate the base pair size of OX DNA fragments generated from an Hae III digest. iNOS RNA expression was detected in U-937 cells by RT-PCR using human iNOS-specific primers. This RT-PCR product was sequenced and found to be identical to the human hepatic iNOS cDNA sequence.
Figure 3B shows a western blot that was performed on whole cell lysates made from 0.5xl06 U-937 cells (U-937), the human B cell line BL-30, and rat macrophages stimulated with LPS (Rat) . INOS expression was detected using an affinity purified rabbit antiserum was raised against the C-terminal 20 amino acids of the rat isoform and recognizes both human and rat iNOS (Kobzik et al . 1993) . The rat isoform, which shares 80% homology with the human isoform, runs slightly below the human isoform on polyacrylamide gels. In addition NO production by U- 937 cells was detected by a photolysis/chemilumincesence assay.
This cell line, therefore, was chosen to study the effects of endogenously synthesized NO on HIV replication. U-937 cells were infected with HIV-l (MN strain) at an MOI of 0.1, washed, and then grown in the presence or absence of N^-monomethyl-L-arginine (L-NMA) , a specific competitive inhibitor of NOS. Ten to fourteen days after infection, p24 levels in the cell supernatant were determined by ELISA. Figures 4A-4B show that endogenously produced NO inhibits HIV replication and HIV reactivation.
Figure 4A shows the results when U-937 cells were infected with HIV-l and then grown in the presence or absence of the NOS inhibitor L-NMA,- and After 8-10 days in culture, p24 levels in the cell supe atants were determined by ELISA. Inhibition of endogenous NO synthesis by L-NMA caused a small but statistically significant increase in p24 antigen levels, with maximal effects seen between 100-250 uM L-NMA. The L-NMA-induced increase in p24 levels was abrogated by the addition of excess L-arginine, the NOS substrate. Thus, both endogenously synthesized NO and exogenous NO appear to inhibit HIV replication. The data represent the mean of
5 duplicate cultures and are representative of three separate experiments.
Since NO produced endogenously by EBV-infected B cell lines inhibits EBV reactivation from a latent to a lytic state, the effect of endogenous NO synthesis on latent HIV infection was analyzed. The U-l cell line (a promonocytic cell line) latently infected with HIV was grown in the presence or absence of L-NMA. The effect on EBV reactivation was determined 2-3 days later by measuring p24 antigen levels in the cell supematants.
Figure 4B shows the results when the latently infected Ul cell line was grown in the presence or absence of L-NMA and TNFa. and after 2-3 days in culture p24 antigen levels were measured in the cell supematants by ELISA. L-NMA caused a dose dependent increase in p24 antigen levels with maximal effects seen at a concentration of lmM (Figure 4B) . The L-NMA-induced increase in p24 levels was abrogated by excess L-arginine but not D-arginine. These results suggest that endogenous NO synthesis inhibits HIV reactivation in a latently infected onocytic cell line. The data represent the mean of duplicate cultures and are representative of one of three similar experiments.
The actions of NO can be broadly classified as either cGMP dependent or independent. For example, much of the inhibitory effect of NO on platelets and smooth muscle is mediated by increases in cGMP levels due to activation of guanylate cyclase.
Figure 5 shows the effect of cGMP on HIV replication. Peripheral blood mononuclear cells were infected with HIV-l and then grown in the presence or absence of SNAP, NAP or the cGMP analog 8-bromo-cGMP. After 5 days p24 antigen levels were measured in the cell supematants. Thus, activation of guanylate cyclase may
be one of the mechanisms by which NO inhibits HIV replication since ImM 8-bromo-cGMP (a cGMP analog) caused a three-fold inhibition of HIV replication (Figure 5) ; however, other mechanisms may also be involved in the N0- induced inhibition of HIV replication since NO-generating compounds can decrease HIV replication 7 fold without significantly inhibiting cellular proliferation (150 uM) . The data represent the mean of duplicate cultures.
The scope of the present invention is not to be limited to the specific embodiments described above. The invention may be practiced other than as particularly described and still be within the scope of the accompanying claims.
Claims
1. A method for inhibiting retroviral replication in a retrovirally infected cell or tissue culture in vitro which comprises contacting said retrovirally infected cell or tissue culture with an amount of nitric oxide or a nitric oxide- delivering, releasing or transferring compound sufficient to inhibit retroviral replication in said retrovirally infected cell or tissue culture.
2. The method of claim 1 which comprises administering gaseous nitric oxide.
3. A method for inhibiting retroviral replication in a retrovirally infected animal which comprises administering to said retrovirally infected animal an amount of nitric oxide or a nitric oxide-delivering, releasing or transferring compound sufficient to inhibit retroviral replication in said retrovirally infected animal.
4. The method of claim 2 which comprises administering a nitric oxide delivering, releasing or transferring compound selected from the group consisting of S-nitrosothiols, compounds that include at least one -0-NO group, N- nitrosoamines, C-nitroso compounds including at least one -C-NO group, nitrates having at least one -0-N02 group, nitroso-metal compounds, N-oxo-N-nitrosoamines, and thionitrates.
5. The method of claim 4 wherein the compound is an S- nitrosothiol.
6. The method of Claim 5 wherein the S-nitrosothiol is selected from the group consisting of an S-nitroso-amino acid, an S-nitroso-polypeptide and an S-nitrosylated protein.
7. The method of claim 5 wherein the S-nitrosothiol is selected from the group consisting of those having the structures :
(i) CH3(CH2)xSNO wherein x equals 2 to 20;
(ii) HS (CH2) xSN0 wherein x equals 2 to 20 ; and
(iii) ONS (CH2) xY wherein x equals 2 to 20 and Y is selected from the group consisting of fluoro, alkoxy, cyano, carboxamido, C3-C6 cycloalkyl, aralkoxy, C2-C6 alkylsulfinyl, arylthio, alkylamino, C2-C15 dialkylamino, hydroxy, carbamoyl, Ci-Cg N- alkylcarbamoyl, C2-C1S N,N-dialkylcarbamoyl, amino, hydroxyl, carboxyl, hydrogen, nitro and aryl; wherein aryl includes benzyl, naphthyl, and anthracenyl groups.
8. The method of claim 5 wherein the S-nitrosothiol is an S-nitroso-ACE inhibitor selected from the group consisting of compounds having the following structure (1) :
(1)
wherein
R is hydroxy, NH2, NHR4, NR4R5, or C-.-C- alkoxy, wherein R4 and R5 are C-.-^ alkyl, or phenyl, or C1-C4 alkyl substituted by phenyl,-
R1 is hydrogen, C1-C7 alkyl, or Cj-C- alkyl substituted by phenyl, amino, guanidino, NHR6, NR6R7, wherein R6 and R7 are methyl or Cj-C4 alkanoyl;
R2 is hydrogen, hydroxy, Ci-C4 alkoxy, phenoxy, or Cx-
C7 alkyl;
R3 is hydrogen, Ci-C4 or C-.-C- alkyl substituted by phenyl; m is 1 to 3; and n is 0 to 2.
9. The method of claim 5 wherein the S-nitrosothiol is an S-nitroso-ACE inhibitor selected from the group consisting of N-acetyl-S-nitroso-D-cysteinyl-L-proline, N-acetyl-S- nitroso-D, L-cysteinyl-L-proline, 1- [4-amino-2- (S- nitroso)mercaptomethyl butanoyl] -L-proline, 1- [2-hexanoyl] -L- proline, 1- [5-guanidino-2- (S-nitroso)mercaptomethyl-pentanoyl] L-proline, 1- [5-amino-2- (S-nitroso) mercaptomethyl-pentanoyl] - 4-hydroxy-L-proline, 1- [5-guanidino-2- (S- nitroso)mercaptomethyl-pentanoyl] -4-hydroxy-L-proline, 1- [2- aminomethyl-3 (S-nitroso) -mercaptomethyl-pentanoyl-L-proline, and S-nitroso-L-cysteinyl-L-proline.
10. The method of claim 5 wherein the S-nitrosothiol is an S-nitroso-ACE inhibitor selected from the group consisting of compounds having structures (2-3) :
wherein
X is oxygen or sulfur,-
-Alf-A2- is CH-NH or -C=N-;
A is ON-S-CH2-CH-C; R is selected from hydrogen, lower (Ci-C4) alkyl, benzyl, benzhydryl, and salt forming ion;
Ri and R2 are independently selected from hydrogen, halogen, lower alkyl, lower alkoxy, halo substituted lower alkyl, nitro, and S02NH2;
0 0 ,0
Z is -C- or -S-
R3 is hydrogen, lower alkyl, halo substituted lower alkyl, phenyl, benzyl, phenethyl, or cycloalkyl; and R4 is hydrogen, lower alkyl, halo substituted lower alkyl, hydroxy substituted lower alkyl, -(CH2)q-N (lower alkyl)2 or -(CH2)q-NH2 and q is one, two, three or four.
11. The method of claim 5 wherein the S-nitrosothiol is an S nitroso-ACE inhibitor selected from the group consisting of compounds having structures (4-11) :
12. The method of claim 3 wherein the retrovirus is selected from the group consisting of human immunodeficiency virus and human T-cell leukemia virus-1.
13. The method of claim 3 wherein the animal is a human.
14. The method of claim 1 wherein the retrovirus is selected from the group consisting of human immunodeficiency virus and human T-cell leukemia virus-1.
15. A method for inhibiting the reactivation of latent retrovirus in a retrovirally infected cell or tissue culture which comprises contacting said retrovirally infected cell or tissue culture with a retrovirus reactivation inhibiting amount of nitric oxide, or a nitric oxide releasing, donating, or transferring substance may be used prophylactically to prevent reactivation of latent retrovirus.
16. A method for inhibiting the reactivation of a latent retrovirus infection in an animal in need thereof which comprises administering to said animal in need thereof an amount of nitric oxide, or a nitric oxide releasing, donating, or transferring substance sufficient to inhibit reactivation of latent retrovirus in said animal.
17. The method of claim 16 wherein the animal is a human.
18. A method for preventing or reversing retroviral latency in a retrovirally infected cell or tissue culture in vitro which comprises contacting a retrovirally infected cell or tissue culture in vitro with a nitric oxide synthase inhibitor or nitric oxide scavenger in an amount sufficient to render the latent retrovirus in the retrovirally infected cell or tissue culture replication-competent.
19. A method for the treatment of a latent retrovirus infection in an animal infected with a latent retrovirus infection which comprises administering thereto (i) a nitric oxide synthase inhibitor or nitric oxide scavenger in an amount sufficient to render the retrovirus infecting said animal replication-competent and (ii) a retroviral replication inhibitory amount of an antiviral agent.
20. The method of claim 19 wherein the nitric oxide synthase inhibitor is nitro-arginine.
21. The method of claim 20 wherein the nitric oxide synthase inhibitor is selected from the group consisting of N6- monomethyl-L-arginine, diphenylene iodonium and related iodonium derivatives, N-nitro-L-arginine methyl ester, N- methyl-L-arginine, N-amino-L-arginine, ornithine, N-imino- ethyl-L-ornithine and ornithine derivatives, N-nitro-L- arginine, methylene blue, trifluoropiperazine, calcinarin, calmadulin binders, and methotrexate.
22. The method of claim 19 wherein the antiviral agent is a purine nucleoside analog.
23. The method of claim 22 wherein the purine nucleoside analog is selected from the group consisting of acyclovir and didanosine.
24. The method of claim 19 wherein the antiviral agent is a pyrimidine nucleoside analog.
25. The method of claim 24 wherein the pyrimidine nucleoside analog is selected from the group consisting of zidovudine, trifluridine and zalcitabine.
26. The method of claim 19 wherein the antiviral agent is selected from the group consisting of a chelating agent, an intercalating agent and an interferon.
27. The method of claim 19 wherein the animal is a human.
28. A composition for the treatment of a latent retrovirus infection in an animal infected with a latent retrovirus infection which comprises (i) a nitric oxide synthase inhibitor or nitric oxide scavenger in an amount sufficient to render the retrovirus infecting said animal replication competent and (ii) a retrovirus replication inhibitory amount of an antiviral agent in a pharmaceutically acceptable carrier.
29. The composition of claim 28 wherein the nitric oxide synthase inhibitor is nitro-arginine.
30. The composition of claim 29 wherein the nitric oxide synthase inhibitor is selected from the group consisting of N*3- monomethyl-L-arginine, diphenylene iodonium and related iodonium derivatives, N-nitro-L-arginine methyl ester, N- methyl-L-arginine, N-amino-L-arginine, ornithine, N-imino- ethyl-L-ornithine and ornithine derivatives, N-nitro-L- arginine, methylene blue, trifluoropiperazine, calcinarin, calmadulin binders, and methotrexate.
31. The composition of claim 28 wherein the antiviral agent is a purine nucleoside analog.
32. The composition of claim 31 wherein the purine nucleoside analog is selected from the group consisting of acyclovir and didanosine.
33. The composition of claim 28 wherein the antiviral agent is a pyrimidine nucleoside analog.
34. The composition of claim 33 wherein the pyrimidine nucleoside analog is selected from the group consisting of zidovudine, trifluridine and zalcitabine.
35. The composition of claim 28 wherein the antiviral agent is selected from the group consisting of a chelating agent, an intercalating agent and an interferon.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AU55271/96A AU5527196A (en) | 1995-04-04 | 1996-03-26 | Inhibiting retroviral replication |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US41604695A | 1995-04-04 | 1995-04-04 | |
US08/416,046 | 1995-04-04 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO1996031217A1 WO1996031217A1 (en) | 1996-10-10 |
WO1996031217A9 true WO1996031217A9 (en) | 1996-11-28 |
Family
ID=23648310
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US1996/004084 WO1996031217A1 (en) | 1995-04-04 | 1996-03-26 | Inhibiting retroviral replication |
Country Status (2)
Country | Link |
---|---|
AU (1) | AU5527196A (en) |
WO (1) | WO1996031217A1 (en) |
Families Citing this family (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE69826528T2 (en) | 1997-12-23 | 2006-02-23 | Amersham Health As | NITROGEN OXIDE RELEASING CHELATE FIGURES AND THEIR USE THERAPEUTIC |
CA2254645A1 (en) * | 1998-11-23 | 2000-05-23 | Pulmonox Medical Corporation | Method and apparatus for treatment of respiratory infections by nitric oxide inhalation |
US6432077B1 (en) | 2000-12-26 | 2002-08-13 | Sensormedics Corporation | Device and method for treatment of surface infections with nitric oxide |
US7335181B2 (en) | 2000-12-26 | 2008-02-26 | Pulmonox Technologies Corporation | Nitric oxide decontamination of the upper respiratory tract |
DE10303196A1 (en) * | 2003-01-28 | 2004-08-12 | Märtz, Hans Helmut | Use of products that release nitric oxide in vivo to treat or prevent infectious diseases in humans or animals |
SE0300971D0 (en) * | 2003-04-03 | 2003-04-03 | Aga Ab | Nitric oxide in the treatment of inflammation |
US7503322B2 (en) * | 2003-09-12 | 2009-03-17 | Harris Michael F | Methods for the treatment of HIV and other viruses |
CA2552735C (en) | 2004-01-07 | 2012-09-11 | Noxilizer, Inc. | Sterilization system and device |
US8017074B2 (en) * | 2004-01-07 | 2011-09-13 | Noxilizer, Inc. | Sterilization system and device |
WO2007057763A2 (en) * | 2005-11-18 | 2007-05-24 | Pulmonox Technologies Corporation | Nitric oxide as an anti-viral agent, vaccine and vaccine adjuvant |
EP2361099B1 (en) | 2009-02-23 | 2012-09-12 | Noxilizer, Inc. | Method for gas sterilization |
CA2830581A1 (en) | 2011-04-04 | 2012-10-11 | Arizona Board Of Regents, A Body Corporate Of The State Of Arizona, Acting For And On Behalf Of Arizona State University | Multifunctional radical quenchers for the treatment of mitochondrial dysfunction |
WO2016133959A1 (en) | 2015-02-17 | 2016-08-25 | Arizona Board Of Regents On Behalf Of Arizona State University | Therapeutic compounds |
AU2016220096B2 (en) | 2015-02-17 | 2020-01-30 | Arizona Board Of Regents On Behalf Of Arizona State University | Phenothiazine analogues as mitochondrial therapeutic agents |
WO2018039077A1 (en) | 2016-08-25 | 2018-03-01 | Arizona Board Of Regents On Behalf Of Arizona State University | Therapeutic compounds |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5047407A (en) * | 1989-02-08 | 1991-09-10 | Iaf Biochem International, Inc. | 2-substituted-5-substituted-1,3-oxathiolanes with antiviral properties |
US5025001A (en) * | 1988-06-15 | 1991-06-18 | Brigham And Women's Hospital | S-nitroso derivatives of ACE inhibitors and the use thereof |
US5002964A (en) * | 1988-06-15 | 1991-03-26 | Brigham & Women's Hospital | S-nitrosocaptopril compounds and the use thereof |
US5380758A (en) * | 1991-03-29 | 1995-01-10 | Brigham And Women's Hospital | S-nitrosothiols as smooth muscle relaxants and therapeutic uses thereof |
-
1996
- 1996-03-26 WO PCT/US1996/004084 patent/WO1996031217A1/en active Application Filing
- 1996-03-26 AU AU55271/96A patent/AU5527196A/en not_active Abandoned
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US5583101A (en) | Use of nitrogen oxide species and adducts to inhibit skeletal muscle contraction | |
WO1996031217A9 (en) | Inhibiting retroviral replication | |
WO1996031217A1 (en) | Inhibiting retroviral replication | |
Baba et al. | Potent and selective inhibition of human immunodeficiency virus type 1 (HIV-1) by 5-ethyl-6-phenylthiouracil derivatives through their interaction with the HIV-1 reverse transcriptase. | |
EP0735890B1 (en) | Mixtures of 2',3'-dideoxy-inosine and hydroxycarbamide for inhibiting retroviral spread | |
Sommadossi et al. | Uridine reverses the toxicity of 3'-azido-3'-deoxythymidine in normal human granulocyte-macrophage progenitor cells in vitro without impairment of antiretroviral activity | |
Sappey et al. | Iron Chelation Decreases NF-k B and HIV Type 1 Activation due to Oxidative Stress | |
Gosselin et al. | Anti-human immunodeficiency virus activities of the beta-L enantiomer of 2', 3'-dideoxycytidine and its 5-fluoro derivative in vitro | |
Malley et al. | Synergistic anti-human immunodeficiency virus type 1 effect of hydroxamate compounds with 2', 3'-dideoxyinosine in infected resting human lymphocytes. | |
KR20010020611A (en) | Antioxidant enhancement of therapy for hyperproliferative conditions | |
WO1996002241A9 (en) | Use of nitrogen oxide species and adducts to inhibit skeletal muscle contraction | |
ES2312884T3 (en) | ANTIVIRAL COMPOSITIONS THAT INCLUDE DERIVATIVES OF PHENYLACETIC ACID. | |
EA012650B1 (en) | Use of [d-meala]-[etval]-cyclosporin for the treatment of hepatitis c infection and pharmaceutical composition comprising said [d-meala]-[etval]-cyclosporin | |
WO1996009406A9 (en) | A method for identifying and using compounds that inactivate hiv-1 and other retroviruses by attacking highly conserved zinc fingers in the viral nucleocapsid protein | |
Pereira et al. | Anti-HIV drug development-an overview | |
AU2018279015B9 (en) | Protective metallothionein analog compounds, their compositions and use thereof in the treatment of pathogenic diseases | |
JPH10139668A (en) | Use of dideoxynucleoside analogue in treatment of infection due to virus | |
CN108463221A (en) | Benzazole compounds stimulate the purposes of immune system | |
Mannick et al. | Nitric oxide modulates HIV-1 replication | |
Baba | Inhibitors of HIV-1 gene expression and transcription | |
US5073571A (en) | Method of inhibiting virus | |
WO1996002268A1 (en) | Inhibition of virus by nitric oxide | |
CA2386325C (en) | Gallium complexes of 3-hydroxy-4-pyrones to treat infection by intracellular prokaryotes, dna viruses and retroviruses | |
Baba et al. | Anti-human immunodeficiency virus type 1 activities and pharmacokinetics of novel 6-substituted acyclouridine derivatives | |
US20210100801A1 (en) | Pharmaceutical composition for stimulating stem cell division and suppressing bacterial virulence |